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Abstract 
 Adipose tissue is one of the most dynamic tissues in the body and is vital 
for metabolic homeostasis. In the case of excess nutrient uptake, adipose tissue 
expands to store excess energy in the form of lipids, and in the case of reduced 
nutrient intake, adipose tissue can shrink and release this energy. Adipocytes are 
most functional when the balance between these two processes is intact. To 
understand the molecular mechanisms that drive insulin resistance or conversely 
preserve the metabolically healthy state in obese individuals, our laboratory 
performed a screen for differentially regulated adipocyte genes in insulin resistant 
versus insulin sensitive subjects who had been matched for BMI. From this 
screen, we identified the type II transmembrane protein tenomodulin (TNMD), 
which had been previously implicated in glucose tolerance in gene association 
studies. TNMD was upregulated in omental fat samples isolated from the insulin 
resistant patient group compared to insulin sensitive individuals. TNMD was 
predominantly expressed in primary adipocytes compared to the stromal vascular 
fraction from this adipose tissue. Furthermore, TNMD expression was greatly 
increased in human preadipocytes by differentiation, and silencing TNMD 
blocked adipogenic gene induction and adipogenesis, suggesting its role in 
adipose tissue expansion. 
 Upon high fat diet feeding, transgenic mice overexpressing Tnmd 
specifically in adipose tissue developed increased epididymal adipose tissue 
(eWAT) mass without a difference in mean cell size, consistent with elevated in 
vii
vitro adipogenesis. Moreover, preadipocytes isolated from transgenic epididymal 
adipose tissue demonstrated higher BrdU incorporation than control littermates, 
suggesting elevated preadipocyte proliferation. In TNMD overexpressing mice, 
lipogenic genes PPARG, FASN, SREBP1c and ACLY were upregulated in eWAT 
as was UCP-1 in brown fat, while liver triglyceride content was reduced. 
Transgenic animals displayed improved systemic insulin sensitivity, as 
demonstrated by decreased inflammation and collagen accumulation and 
increased Akt phosphorylation in eWAT. Thus, the data we present here suggest 
that TNMD plays a protective role during visceral adipose tissue expansion by 
promoting adipogenesis and inhibiting inflammation and tissue fibrosis.  
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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2Obesity as an epidemic 
 
The obesity epidemic is a major health burden that humanity faces in 
modern times. Given the virtually unlimited food availability in developed 
countries, obesity has been thought to emerge in economically rich countries. In 
the United States obesity prevalence among adults was 34.9% in 2011-2012 (1). 
However, low and middle-income countries have also been suffering from obesity 
and related disorders. According to WHO, increase rate of overweight and obese 
children in these countries is 30% higher than in developed countries. The 
prevalence of obesity has doubled worldwide since 1980, which signifies that it is 
indeed a global problem (2).  
Obesity is excess fat accumulation in the body by definition. The most 
common tool to estimate obesity in adults is body mass index (BMI), which is 
calculated by dividing weight by square of height (kg/m2) and first described by 
Adolphe Quetelet in 1832 (3-5). According to World Health Organization (WHO) 
guidelines, individuals with a BMI between 25-29.9 are considered to be 
overweight and those who have a BMI over 30 are categorized as obese. Even 
though it is debated whether BMI, fat distribution or total body fat mass is the 
predictor, it is now well established that obesity is associated with plethora of 
metabolic complications such as type II diabetes, cardiovascular disease, 
nonalcoholic fatty liver disease and cancer (6, 7).  
 
3Adipose tissue biology 
 
Energy storage is vital for all organisms, and lipids serve as an efficient 
way to store excess energy. Regardless of their complexity and the type of lipids 
to be stored, most organisms have specialized compartments to deposit fat (8). 
Caenorhabditis elegans, for example, stores lipid as triacylglyceride (TAG) in 
intestinal epithelial cells (9, 10) whereas Drosophila melanogaster has a 
specialized organ termed the ‘fat body’ (11).  In mammals, adipose tissue, the 
body’s fat reservoir, is a connective tissue that is composed of adipocytes, blood 
vessels, neurons, extracellular matrix and immune cells (12).  Adipocytes occupy 
most of the space in adipose tissue, and similar to the lower organisms, take up 
and convert nutrients into triglycerides (13). However, over the last decade, 
adipose tissue has become recognized as a dynamic endocrine organ that is a 
major regulator of energy homeostasis rather than an inert storage organ (14-
16). Therefore, much effort has been devoted to fully understand its role in 
metabolic diseases such as type II diabetes.  
 Despite excess accumulation of fat, which is associated with many 
morbidities, individuals lacking adipose tissue also display extreme insulin 
resistance, similar to metabolically unhealthy obese subjects. Mutations in genes 
such as 1-acylglycerol-3-phosphate acyltransferase (AGPAT2) and Berardinelli-
Seip congenital lipodystrophy 2 (seipin) (BSCL2) causes lipodystrophy, a 
congenital disease characterized by partial or total loss of adipose tissue (17-19). 
4People with this rare condition are insulin resistant and have high levels of 
circulating glucose, hypertriglyceridemia and hepatic steatosis. Mouse models of 
lipodystrophy also mimic the human phenotype (20). Dominant-negative AZIP/F-
1 inhibits DNA binding of BZIP transcription factors such as CCAAT/enhancer-
binding protein alpha (C/EBP) and Jun. These mice are lipodystrophic and 
exhibit a similar phenotype to lipodystrophic humans (21, 22). Moreover, Agpat2 
null mice were insulin resistant and also had fatty liver and hyperglycemia (23). 
Thus, adipose tissue is essential for metabolic health.  
 
Energy storage by adipose tissue 
 
Adipocytes are specialized to store energy in the form of fat. They respond 
to several nutritional cues and hormones to manage pathways involved in lipid 
storage (24). After feeding, insulin stimulates glucose uptake in adipose tissue by 
binding its receptor on the plasma membrane of adipocytes (25). Insulin binding 
to its receptor, a tyrosine kinase, triggers a signaling cascade that results in 
activation of phosphoinositide 3-kinase (PI3K) and the AKT protein kinase (also 
known as protein kinase B) (26, 27). AKT activation mediates many of the 
metabolic effects of insulin as it is the upstream kinase for many cellular 
metabolic pathways including de novo lipogenesis (28). AKT activates mTORC1, 
which phosphorylates S6 kinases (S6K1 and S6K2) and sterol regulatory 
element binding protein-1 (SREBP1) (29). Another transcription factor, 
5carbohydrate-responsive element-binding protein (ChREBP), is also activated by 
cellular glucose uptake (30). SREBP1 and ChREBP regulate the expression of 
various lipogenic enzymes (31-33). In peripheral insulin target tissues, activated 
AKT is required for insulin-mediated glucose uptake. It achieves this function 
through activation of Akt substrate of 160 kDa (AS160) (34). Phosphorylated 
AS160 then binds to glucose transporter type 4 (GLUT4) vesicles and stimulates 
their translocation to the plasma membrane (25, 35-37). Glucose that is taken up 
by adipocytes is not only utilized for de novo fatty acid synthesis, but it also 
provides the glycerol backbone for triacylglyceride (TAG) (38). Fatty acid 
synthase (FASN) is an enzyme complex that along with acetyl-coA carboxylase 
(ACC) converts acetyl-coA into fatty acids (39). Free fatty acids, which are 
augmented in the circulation upon feeding, are also taken up by adipocytes. 
Along with passive diffusion, cluster of differentiation 36 (CD36) and fatty acid 
binding protein 1 (FABP1) are involved in free fatty acid uptake in adipocytes (40-
43). Moreover, insulin increases the expression of lipoprotein lipase, the enzyme 
that breaks down triglycerides bound in very low-density lipoprotein (VLDL) or 
chylomicrons and promotes fatty acid uptake into adipocytes (44). Fatty acids 
within the cell are activated and finally esterified into TAG and stored in lipid 
droplets. 
As previously mentioned, adipocytes are also capable of breaking down 
TAG into free fatty acids and glycerol by lipolysis, which is a multistep process. 
Catecholamine signaling is the main pathway that stimulates lipolysis (45, 46). 
6The beta-adrenergic receptor is stimulated by catecholamines upon fasting, 
which in turn elevates cAMP levels and activates protein kinase A (PKA) (46, 47). 
Consecutive breakdown of TAG into free fatty acids and glycerol involves three 
enzymes; adipocyte triglyceride lipase (ATGL), hormone sensitive lipase (HSL) 
and monoacylglcerol lipase (MGL), the first two of which require phosphorylation 
for activation (48, 49). Similar to HSL, Perilipin 1 (PLIN1), an adipocyte-specific 
lipid droplet protein, is also phosphorylated by PKA and facilitates HSL 
localization on lipid droplets (50).  Conversely, insulin strongly inhibits lipolysis by 
activating phosphodiesterase 3 (PDE3), which degrades cAMP. Hence, abated 
cAMP levels in insulin-stimulated cells inhibit lipolysis (51, 52).  
 
Adipose tissue as an endocrine organ 
 
 Adipocytes and other cell types residing in the adipose tissue secrete a 
variety of molecules, termed adipokines that act as endocrine and paracrine 
hormones. Leptin was the first known adipokine, discovered in 1994 (15). It binds 
to the leptin receptor, which is expressed in many tissues including the 
hypothalamus (53, 54). The metabolic function of leptin has been widely studied, 
and a significant correlation between circulating leptin levels and fat storage has 
been shown (55, 56). Leptin not only suppresses food intake through 
hypothalamic signaling, and mice lacking leptin or its receptor are hyperphagic 
and develop extreme obesity and insulin resistance. Leptin also activates fatty 
7acid oxidation in muscle and improves glucose metabolism in streptozotocin 
(STZ), β-cell toxicant, treated mice (57, 58). Another adipokine secreted from 
both brown and white adipocytes is adiponectin, which has insulin sensitizing 
effects (59). Mice lacking adiponectin were first generated by Nawrocki et al. and 
demonstrated severe hepatic insulin resistance in liver but not in other peripheral 
tissues. Adiponectin null mice exhibit a dampened response to thiazolidinediones 
(TZDs), a class of insulin sensitizing drugs that function via PPARγ activation 
(60). On the other hand, despite excessive weight gain, transgenic mice 
overexpressing adiponectin on the leptin-deficient ob/ob background have a 
vastly improved metabolic profile (61). Adipocytes also release pro-inflammatory 
cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and 
monocyte chemoattractant protein 1 (MCP1) upon various conditions, and these 
factors regulate adipose tissue metabolism (62-64). Adipose tissue TNF-α 
expression is increased in obese states, and inhibition of this cytokine using 
specific antibodies improved glucose uptake in obese rodents (65). Similarly, 
circulating MCP1 levels are decreased by weight loss, and insulin-stimulated 
glucose uptake was reduced in MCP1-treated adipocytes (66, 67).  Recently, 
studies demonstrated systemic metabolic effects of brown adipose tissue 
transplantation, which attracted attention to endocrine functions of brown adipose 
tissue (68-70). For instance, brown adipose tissue  (BAT) contributes to plasma 
levels of fibroblast growth factor 21 (FGF21), a factor that stimulates thermogenic 
gene expression (70, 71). 
8Adipose tissue depots  
 
In mammals, white adipose tissue (WAT) is distributed in various 
anatomical depots (72, 73). Subcutaneous depots store more than 80 % of total 
body fat and constitute the largest portion of WAT (74). In humans, 
subcutaneous adipose tissue (SAT) is found in the thighs, hips and abdomen, 
whereas visceral adipose tissue (VAT), also known as intra-abdominal fat, is 
located around vital organs in the peritoneum (75). Similarly, rodents have 
subcutaneous fat depots of which inguinal and axillary fat represent the majority, 
whereas VAT is mostly distributed in the mesenteric, perigonadal and 
retroperitoneal areas (76, 77).  
Differences in lipid handling, gene signatures, precursor cells and 
physiology between subcutaneous and visceral fat have been broadly studied 
(78-81). Location of WAT depots is associated with some metabolic outcomes. 
Growing evidence suggests that VAT is correlated with metabolic disorders to a 
greater extent than SAT (82-84). According to the prevailing “portal vein 
hypothesis’, VAT is in close proximity to vital organs in the abdomen and lipids 
released from VAT reach the liver directly through the portal vein (85-87). Given 
that ectopic lipid deposition in liver may contribute to systemic insulin resistance, 
one possibility is that due to its location VAT expansion is a major risk factor for 
metabolic disease (74, 88). However, a transplantation study performed by Tran 
et al. demonstrated that SAT, when transplanted into the intra-abdominal area, 
9can improve insulin sensitivity. This suggests that differences between SAT and 
VAT are not only related to the anatomical location, but also other inherent 
mechanisms play a role in metabolic function of these depots (77). In fact, 
studies focusing on the gene signature differences between depots revealed that 
expression of developmental genes such as T-box (TBX) and HOX genes varies 
between SAT and VAT (89, 90). In humans and mice, Tbx15 is expressed more 
highly in subcutaneous depots than in VAT. These findings suggest that different 
developmental programs play role in formation of these depots. Adipogenic 
genes such as PPARγ and C/EBPα, however, were uniformly distributed 
between depots in mice (91). Moreover, receptor composition is distinct between 
SAT and VAT.  
Glucocorticoid and adrenergic receptors display regional variation in 
expression and have prominent density in visceral depots (92, 93). Even though 
the exact molecular mechanisms still remain unclear, increased central obesity 
after glucocorticoid exposure may be explained by high expression of 
glucocorticoid receptor in VAT (94). Lipid handling also varies between depots. 
VAT stores dietary fat more efficiently than SAT (95) and in hyperinsulinemia, 
postprandial free fatty acid release and lipolysis is greater in obese people with 
upper body/visceral obesity versus subjects with lower body obesity (78, 96). 
Finally, when the secretome was analyzed in AT explants, VAT displayed a 
greater abundance of secreted proteins (97).  
10
BAT differs from WAT not only by location but also by metabolic and 
physiological function (98). Until it was detected in adults, BAT had long been 
thought to appear only in babies to regulate the body temperature (99, 100). 
Many recent studies have focused on approaches to activating the thermogenic 
function of BAT, thereby utilizing the excess caloric energy to a tissue to produce 
heat rather than contributing to excess fat storage (101, 102). Brown adipocytes 
are characterized by high expression of uncoupling protein 1 (UCP-1), high 
mitochondrial density and the presence of multiple small (multilocular) lipid 
droplets, distinct from the single, large (unilocular) droplet typical of white 
adipocytes (103). During cold stress, β-adrenergic receptors on brown adipocyte 
membranes are stimulated by catecholamines. Subsequently, down stream 
molecules such as cAMP/PKA are stimulated, which in turn increase UCP1 
expression and lipolysis (104, 105). Brown adipocytes can also take up high 
amounts of glucose and free fatty acids from the circulation, which can be utilized 
in thermogenesis (106).  It has recently been realized that BAT is not the only 
depot where thermogenesis occurs. Even though the origin of these thermogenic 
cells is controversial, it is now well established that brown-like adipocytes are 
present in white adipose depots (107). These so-called “Brite” or “beige” cells 
express UCP1 and can activate the thermogenic network upon cold exposure or 
direct stimulation of the β-adrenergic receptor (108, 109). These cells can 
increase energy expenditure and potentially protect against obesity (110). 
11
Therefore, strategies aiming to increase browning within WAT have been 
attractive for therapeutic purposes (111).  
 
Adipose tissue formation 
 
In vivo adipose tissue formation  
Studies that used microscopic imaging in human embryos and fetuses 
showed that AT first appears in the 14th week of gestation. Even though there is 
extensive AT growth between the 14th and 24th weeks of gestation, elevated 
nutrient uptake also gives rise to rapid postnatal expansion of adipose depots 
(112-114). Adipocytes are believed to originate from mesenchymal stem cells 
(MSCs), which can also transform into osteoblasts, myocytes and chondrocytes 
(115). WAT contains various types of cells including adipocyte precursors, 
endothelial cells, neurons, immune cells and mature adipocytes (116). Using 
collagenase digestion and centrifugation, lipid-laden adipocytes can be 
separated from other cells in the AT, and the remaining cells are called the 
stromal vascular fraction (SVF). Some cells from the SVF fraction can 
differentiate into cells of mesenchymal origin including adipocytes, myocytes and 
osteoblasts in vitro (117, 118). These multipotent cells are termed adipose 
tissue-derived stromal cells (ADSC). Even though these cells have successfully 
been differentiated into adipocytes in vitro, their adipogenic ability is limited in 
vivo (119).  
12
Much effort has been devoted to find the precise white adipocyte 
precursors that are also able to form a fat pad in vivo. Approaches include sorting 
the SVF fraction into subpopulations using specific cell surface markers and flow 
cytometry. Of these cells, those that are CD24+ not only have in vitro adipogenic 
potential, but they are also capable of forming a fat pad in the lipodystrophic A-
ZIP mice but not in wild type mice (120). Using a similar method and a 
genetically labeled mouse model, Graff and colleagues demonstrated the 
presence of a committed cell population that resides in adipose tissue, expresses 
mural cell markers such as PDGFRβ and can develop into a fat pad even in wild 
type mice (121). These data were supported by several others, who 
demonstrated that cells within the AT vasculature can convert into mural cells, 
which can proliferate and differentiate into mature adipocytes (116, 122-124). 
Some studies also indicated that when transplanted into mice and treated with 
PPARγ agonists, hematopoietic stem cells can develop into adipocytes (125). 
Even though studies based on cell surface markers shed light on the field of 
adipocyte progenitors, the specificity of these markers is a challenge, especially 
for in vivo studies.  
 Despite some limitations, in vivo tracing studies based on the Cre/Lox 
reporter system has become a gold standard to elucidate adipocyte progenitors 
(103, 126). Using this method, it has been discovered that white and brown 
adipocytes do not arise from the same precursors. Instead, brown adipocytes are 
derived from progenitor cells expressing myogenic factor 5 (Myf5) and paired 
13
box-7 (Pax7), which also differentiate into myocytes (127, 128). However, these 
findings were challenged by a study that combined Myf5-Cre with ‘LoxP–
membrane targeted dTomato–LoxP–membrane targeted GFP’-also known as 
mT/mG- dual fluorescence reporter mice. Myf5Cre-mT/mG mice revealed that 
Myf5+ cells are not the only source of brown adipocytes. Instead mature white 
and brite/beige adipocytes in specific WAT depots also arise from these 
progenitors (129).  In vivo tracing studies have also initiated an interesting debate 
on whether the origin of brite/beige cells that arise in WAT. One of the 
hypotheses suggests that beige adipocytes in WAT emerge through a 
transdifferentiation or interconversion mechanism. In other words, unilocular 
white adipocytes undergo some phenotypic changes to develop into brite/beige 
adipocytes with multiple lipid droplets and high UCP1 expression. This 
hypothesis has been supported by studies from two different groups (130-132). 
On the other hand, findings from a study that used a permanent adipocyte 
labeling approach argued that brite/beige adipocytes are formed via de novo 
differentiation from progenitor cells (133). Further studies will provide a better 
understanding of the in vivo origin of white, brown and beige adipocytes (Figure 
1.1).  
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Adipogenesis 
 
 Adipocyte precursor cells undergo a process called adipogenesis, which is 
critical for adipose tissue development and expansion (135-137). Hence, forming 
adipocytes requires strict regulation that involves many intra and extracellular 
pathways. This section will focus on the molecular mechanisms that are 
implicated in adipocyte differentiation and the cellular models that have been 
used to elucidate these mechanisms.  
 
In vitro and in vivo models of adipocytes 
Adipogenesis is a well-studied developmental program, and availability of 
preadipocyte cell culture models has contributed a great deal to studies that 
investigate adipocyte differentiation (138). 3T3-L1 cells are the most established 
cell line through which many aspects of adipogenesis have been examined. 
These cells are already committed preadipocytes, and they were originally 
derived from Swiss 3T3 mouse embryos (139). 3T3-L1 cells are responsive to 
adipogenic stimuli and can easily convert into adipocytes in culture. 3T3-F442A 
preadipocytes were also isolated from Swiss 3T3 cells (140) and serve as a 
useful model for adipogenesis. They are considered to be in the later stage of 
commitment (138). Furthermore, multipotent stem cell lines that can differentiate 
into multiple lineages are frequently utilized as in vitro models. C3H10T1/2 cells 
were derived from C3H mouse embryos (141, 142). Interestingly, these cells 
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commit to an adipogenic lineage upon induction with bone morphogenic protein 4 
(BMP4) prior to stimulus with an adipogenic cocktail including glucocorticoids, 
cyclic AMP agonists and insulin (143). There has also been much effort to 
establish human adipocyte models (144-147). The Simpson-Golabi-Behmel-
Syndrome (SGBS) cell strain was first isolated from the subcutaneous adipose 
tissue of an infant with the syndrome of the same name. Even though they are 
not immortalized, they have a high capacity to proliferate and differentiate into 
adipocytes, even at later passages (148). SGBS cells differentiate into 
adipocytes under very similar conditions as 3T3-L1 cells; however, they require 
an absence of serum and the presence of PPARγ agonists in the differentiation 
media. SGBS cells acquire multiple lipid droplets, even in the early time points of 
differentiation. Once they become adipocytes, glucose uptake is stimulated and 
lipolysis is inhibited upon insulin treatment in these cells (149). Finally, human 
embryonic and inducible pluripotent stem cells have been utilized as in vitro 
adipocyte model (150-155). These multipotent cells are useful to elucidate the 
molecular mechanisms implicated in adipogenesis, especially because cells 
isolated from patients may give insight into the role of adipocytes in the 
pathogenesis of various metabolic diseases such as lipodystrophy. However, 
monolayer cell culture models have some limitations for unveiling the role of 
physical properties like cell shape and tension, and extracellular matrix 
interactions in adipogenesis and adipocyte function. Three dimensional adipocyte 
culture models that utilize extracellular matrix gels or adipose tissue organoid 
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models in which tissue fragments are embedded in collagen scaffolds will be of 
great use in exploring these aspects of adipose tissue formation (138).  
 
Transcriptional regulation of adipogenesis 
Adipogenesis is a two-step process that is regulated by many factors. In 
the first step, multipotent mesenchymal stem cells are committed to the 
adipocyte lineage. Committed fibroblast-like preadipocytes then undergo several 
changes in morphology and gene expression to form lipid droplet-containing 
mature adipocytes. Therefore, this step can be called terminal differentiation 
(137, 156, 157). Developmental pathways, DNA modifiers, extracellular matrix 
(ECM) composition and transcription factors are implicated in both phases of 
adipogenesis (136, 158, 159).  
 Several lines of evidence suggest that fate of MSCs can be determined by 
the stiffness of the milieu in which they reside (160-163). Dense or stiff ECM has 
been shown to favor osteogenic and myogenic differentiation but not 
adipogenesis (162). Cells displayed greater attenuation in adipogenesis when 
placed in dense gels compared to softer matrices (164). Matrix 
metalloproteinases (MMP) are enzymes that cleave ECM proteins (165). Several 
studies demonstrate that MMP activity is required for adipogenesis and in vivo 
adipose tissue formation (166-168). In cultured cells, cell shape and confluence 
are also important determinants of the cell fate. Both of these factors affect 
adipogenesis by modulating the RHO signaling pathway and the cytoskeleton 
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(169, 170). Once cells are committed to the adipogenic lineage, further events 
are required to transform preadipocytes into adipocytes. Many inhibitory and 
stimulatory molecules modulate this process (114). β-catenin-mediated canonical 
Wnt signaling has been shown to inhibit adipogenesis in various cell culture 
models whereas activating non-canonical Wnt5B signaling stimulated 
adipogenesis in 3T3-L1s (171-174). Different transforming growth factor beta 
(TGFβ) family members have been implicated in adipocyte differentiation. TGFβ 
inhibited adipogenesis in NIH3T3 cells that stably overexpressed adipogenic 
transcription factors such as C/EBPα or PPARγ (175). Furthermore, 
overexpression of Smad3 and Smad2 inhibited 3T3-F442A preadipocyte 
differentiation (176). These results, however, were not supported by in vivo 
studies demonstrating that Smad3 knockout mice did not gain weight upon high 
fat diet (HFD) feeding (177).  
 The major transcription factors involved in early differentiation include 
cAMP response element binding protein (CREB), C/EBPδ, C/EBPβ, signal 
transducer and activator of transcription 5A (STAT5A), krüppel-like factor (KLF4) 
and early growth response 2 (EGR2 or KROX20) (178-183). These transcription 
factors respond to different stimuli in adipogenic media. 3-isobutyl-1-
methylxanthine (IBMX), for example, stimulates protein kinase A (PKA) 
activation. PKA then phosphorylates CREB, and this event is followed by 
elevated C/EBPβ expression (184). KROX20 and KLF4 expression are also 
increased 2-4 hours after stimulation, which up-regulates C/EBPβ expression 
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(182, 183). C/EBPβ activation depends on phosphorylation by various kinases 
such as mitogen activated protein kinase (MAPK), cyclin dependent kinase 2 
(CDK2) and glycogen synthase kinase 3 beta (GSK3β) (185, 186). 
Conformational changes in phosphorylated C/EBPβ facilitate its DNA binding 
(187). Acetylation is also involved in C/EBPβ activation, whereas ubiquitination 
and SUMOlation inhibit C/EBPβ via proteasomal degradation (187, 188). Mitotic 
clonal expansion is a characteristic event in early adipogenesis. Even though it is 
controversial previous studies suggest that 3T3-L1 cells undergo one or two 
rounds of cell cycle before they start expressing the adipocyte phenotype (189, 
190). C/EBPβ has been shown to positively regulate some cell-cycle genes to 
enable mitotic clonal expansion (191).  
 In terminal differentiation, C/EBPβ directly binds to the C/EBPα and 
peroxisome proliferator activated receptor-γ (PPARγ) promoters (192, 193).  
C/EBPα and PPARγ are the major transcription factors that not only promote 
adipogenesis but also maintain differentiated adipocyte function (194). PPARγ is 
considered to be the ‘master regulator’ of adipogenesis mostly because it is both 
necessary and sufficient to drive adipocyte differentiation (Figure 1.2) (195). 
Alternative PPARγ promoters result in two isoforms of this transcription factor: 
PPARγ1 and PPARγ2, the latter of which is exclusively expressed in adipocytes 
(196-198). PPARγ is a nuclear hormone receptor that binds to the DR-1 
sequence on DNA subsequent to heterodimer formation with retinoid X receptor 
(RXR) (199). Similar to other nuclear receptors, PPARγ is also activated upon 
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ligand binding. Even though it has been suggested that some polyunsaturated 
fatty acids and eicosanoids bind to and activate PPARγ, endogenous ligands 
with higher binding affinities remain unknown (200). Synthetic ligands such as 
thiazolidinediones (TZDs) have been used to promote adipogenesis in some in 
vitro cell culture models such as SGBS cells. They have also been utilized as 
drugs in type II diabetes patients to enhance PPARγ activity and its insulin 
sensitizing effects (201). PPARγ is also regulated by C/EBPα and PPARγ and 
C/EBPα reciprocally activate each other (193, 202-204). Interestingly, studies by 
Lazar and Mandrup also showed that C/EBPα and PPARγ share many targets 
and cooperate to activate important adipogenic genes (205, 206). Both C/EBPα 
and PPARγ target genes that are involved in mature adipocyte function such as 
adiponectin, HSL and fatty acid binding protein 4 (FABP4) (207-210). PPARγ 
also regulates lipid metabolism, glucose homeostasis and adipokine secretion 
(211).  
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Figure 1.2 
 
 
 
Figure 1.2: Extracellular and intracellular factors involved in adipogenesis 
In the first step of adipogenesis, mesenchymal stem cells commit to the 
adipogenic lineage. Developmental pathways such as WNT and TGFβ are 
involved in the negative regulation of this step. Dense extracellular matrix and 
sparse cell confluency inhibits adipogenic commitment. In the second step, so-
called terminal differentiation, adipogenic stimuli activate a plethora of 
transcription factors that promote mitotic clonal expansion (MCE) and stimulate 
the expression of C/EBPα and PPARγ. BMP2, BMP4 and WNT5b signaling 
positively regulate adipocyte differentiation. Modified from Cristancho and Lazar, 
2011 (114).  
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Adipose tissue expansion in obesity- adipose tissue remodeling 
 
Adipose tissue is very dynamic and can expand up to 15-fold beyond its 
original volume when there is a positive energy balance (116). It is also capable 
of reducing its volume rapidly upon nutrient deprivation by mobilizing lipids to fuel 
other tissues in times of need (24). Adipose tissue remodeling upon different 
nutrient and energy expenditure situations is a complex phenomenon in which 
many factors such as adipocytes, immune cells, vasculature and the extracellular 
matrix are implicated (12). In this section, I will summarize the events that occur 
in adipose tissue during obesity and eventually contribute to systemic insulin 
resistance.  
Until recently, it was hypothesized that adipocyte number was 
predetermined at an early age and was very unlikely to change with nutritional 
state. However, a study by Spalding et al. showed that approximately 10% of 
adipocytes renew annually, which generated a new concept in understanding the 
mechanisms of adipose tissue expansion (212). It is now largely accepted that 
adipose tissue expands by two mechanisms. In hypertrophy, mature adipocytes 
enlarge in cell size. In hyperplasia, however, adipocyte number is increased. 
Some studies suggested that mature adipocytes undergo dedifferentiation and 
form progenitor cells, which can redifferentiate into adipocytes (213, 214). 
However, hyperplasia will refer to de novo adipocyte differentiation from now on, 
as mature adipocytes are post mitotic. 
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It has been debated whether adipose depots have different adipogenic 
capacities (215, 216). Primary preadipocytes isolated from subcutaneous 
adipose tissue have higher competence to differentiate in culture, whereas those 
isolated from visceral depots either do not differentiate or have very low 
differentiation potential (217, 218). It could be argued that a lack of unknown 
local factors ex vivo is the reason why visceral preadipocytes cannot differentiate 
into adipocytes. One study addressed the question of whether fat depots have 
different adipogenic potential in vivo and demonstrated that a long term HFD 
resulted in a significant increase in the number adipocyte progenitor cells in 
subcutaneous but not visceral adipose tissue. The same study also suggested 
that hypertrophy is the main expansion mechanism for visceral adipose tissue 
while subcutaneous depots expand via hyperplasia (219).   
 Conversely, recent studies using adipocyte-tracing techniques implied that 
higher levels of adipogenesis/hyperplasia occur in visceral adipose tissue 
compared to subcutaneous fat depots in mice. A mouse model generated by 
Scherer and colleagues determined that adipose tissue is expanded by 
hypertrophy at the early time points after HFD challenge in both depots. 
However, visceral adipose tissue undergoes hyperplasia during prolonged HFD 
feeding (133). These results were further supported by a recent study showing 
that visceral adipose tissue expands via hyperplasia upon HFD feeding. Using 
BrdU labeling at different time points of HFD feeding, it was also demonstrated 
that proliferation of adipocyte progenitors was significantly increased in visceral 
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adipose depots whereas subcutaneous adipose tissue did not show any 
significant increase in progenitor proliferation during the first week of dietary 
challenge (220). Regardless of the mechanism, expansion occurs to increase 
adipose tissue energy storage capacity. Hence, proper adipose tissue expansion 
could be considered as a beneficial activity for animals (Figure 1.3) (221-224).  
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Figure 1.3  
 
 
 
Figure 1.3 Two mechanisms of adipose tissue expansion 
In lean adipose tissue, mature adipocytes are surrounded by proper vasculature, 
loose extracellular matrix and pro-inflammatory (M1) macrophages. Upon excess 
nutrient intake and decreased energy expenditure, adipose tissue expands via 
two ways. In hypertrophy, mature adipocytes undergo cell enlargement to meet 
increased demand for energy storage. A rapid increase in cell size results in 
cellular stress, inflammation, hypoxia and finally cell death. Proinflammatory 
macrophages are, in turn, infiltrated into adipose tissue, which stimulate adipose 
tissue insulin resistance. In hyperplasia, however, adipocyte precursors are 
recruited to make new functional adipocytes. Such expansion leads to healthier 
expansion of adipose tissue, which is characterized by adipocytes that are insulin 
sensitive, the presence of anti-inflammatory (M2) macrophages and efficient 
vascularization.  
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Blood vessel formation is vital for tissue expansion but cannot always 
keep up with the rapid increase in adipose tissue volume. Therefore, some cells 
become hypoxic in early obesity (223). Hypoxia inducible factor 1 alpha (HIF-1α) 
is regulated by oxygen levels in the cellular microenvironment (225). Hypoxia and 
HIF-1α are implicated in adipose tissue dysfunction via several proposed 
mechanisms such as reducing adiponectin levels as well as stimulating 
inflammation and fibrosis (226-228). Extracellular matrix (ECM) proteins and 
proteinases that cleave these proteins are implicated in adipose tissue 
expansion. As mentioned before, an environment that allows adipocytes to 
manipulate their differentiation, cell shape and volume is essential for their 
function. Thus, it is not surprising that ECM accumulation and fibrosis is 
associated with rapid and unhealthy adipose tissue expansion in addition to 
stress pathway stimulation and inflammation (229). Many ECM proteins are 
targets of the TGFβ signaling pathway. Connective tissue growth factor (CTGF) 
for instance is involved in tissue fibrosis and inhibits adipogenesis (230, 231). 
Furthermore, various types of collagens have been investigated in the context of 
adipose tissue expansion and metabolic dysfunction (232). Expressions of many 
collagens are increased in obese mice compared to wild type controls (233, 234). 
Collagen VI is mainly expressed in adipose tissue and forms a heterotrimer with 
three alpha chains. Among them, disruption of alpha 1 results in a knockout 
phenotype. In both ob/ob and high fat diet-fed mice, Col6a1 null mice displayed 
larger adipocytes yet a better metabolic phenotype, which was attributed to 
27
reduced ECM stress during adipose tissue expansion (233). This phenomenon 
has also been observed in many other genetic models and is termed “healthy 
adipose tissue expansion” (61, 235, 236). The function of matrix 
metalloproteinases (MMPs) and tissue inhibitor of MMPs (TIMPs) has also been 
investigated in adipocytes (237). For example, mice with MMP14 (MT1-MMP) 
haploinsufficiency demonstrated decreased weight gain, small adipocytes and a 
lipodystrophic phenotype (167, 238). Male TIMP-2 knockout mice also developed 
insulin resistance during HFD (239). Taken together, these studies suggested a 
functional role for MMPs and TIMPs in the regulation of adipose tissue 
expansion.  
There is substantial number of immune cells present in adipose tissue, 
which increases significantly in obesity (240). Cell death occurs in rapidly 
enlarged adipocytes, and one hypothesis is that phagocytic macrophage 
infiltration into adipose tissue serves to eradicate dead cells. Therefore, 
especially in the visceral adipose depot, these newly immigrated macrophages 
form ‘crown like structures’ consisting of macrophages surrounding dead 
adipocytes (241, 242). Several studies have demonstrated that pro-inflammatory 
cytokines are increased in obese adipose tissue, are secreted by macrophages, 
and are implicated in adipose tissue remodeling in obesity (65, 243-245). This is 
not to say all the macrophages recruited into adipose tissue are metabolically 
harmful. Macrophages have the capacity to take up excess lipids upon fasting 
and weight loss, which might be an adaptive response to protect adipose tissue 
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from potentially toxic levels of free fatty acids (246, 247). Moreover, some reports 
have suggested that M2 (anti-inflammatory) macrophages secrete 
catecholamines and promote browning of white adipose tissue upon cold 
exposure (111, 248).  Furthermore, the two macrophages types display opposite 
phenotypes in terms of secreting pro- or anti-inflammatory cytokines. M1 (pro-
inflammatory) macrophages are abundant in obese adipose tissue, whereas lean 
fat has a higher number of M2 (anti-inflammatory) macrophages. Surface 
markers such as CD11c are utilized to distinguish M1 macrophages from M2 
macrophages, as the ratio between them is now used as indicator of the adipose 
tissue inflammatory state (249-251).   
Recently, it was shown that when inflammation is impaired specifically in 
adipocytes, in vivo adipogenesis was attenuated and mice displayed ectopic lipid 
deposition, systemic inflammation and insulin resistance (252). Adipose tissue 
inflammation has long been associated with systemic insulin resistance and type 
II diabetes.  Many factors contribute to inflammation-mediated adipose tissue 
dysfunction. First, adipokine secretion is affected in the obese state (253-256). 
Monocyte chemoattractant protein-1 (MCP-1) is released by stressed adipocytes 
that are stimulated by nutrient overload, which attracts pro-inflammatory 
macrophages into adipose tissue (254, 257). As previously mentioned, pro-
inflammatory M1 macrophages secrete tumor necrosis factor alpha (TNF-α), 
interleukin 1 beta (IL-1β) and interleukin 6 (IL-6), which can have deleterious 
effects on insulin signaling (258, 259). Free fatty acids that are not properly 
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stored in obese adipose tissue and lipopolysaccharide (LPS) from the gut 
microbiota activate the toll like receptor 4 (TLR4) pathway and stimulate adipose 
tissue inflammation (260, 261). How inflammation causes systemic insulin 
resistance is not fully understood. One mechanism suggests that TNF-α along 
with saturated free fatty acids activate c-Jun NH2-terminal kinase (JNK) and 
inhibitor of nuclear factor κβ kinase β (IKKβ) to phosphorylate Ser-307 of IRS and 
suppress insulin signaling (261, 262). Pro-inflammatory cytokines can also 
stimulate lipolysis and repress triglyceride synthesis by inhibiting PPARγ (263-
265). 
 
Insulin resistance  
 
 The balance between lipogenesis and lipolysis in adipose tissue is of great 
importance in maintaining glucose and lipid metabolism. Dysfunctional adipose 
tissue is characterized by diminished lipogenesis, reduced GLUT4-mediated 
glucose transport and stimulated lipolysis, all of which result in inefficient storage 
of lipids (24, 262). Both hyperphagia (increased food intake) and leakage from 
adipose tissue cause elevated levels of free fatty acids in the circulation, which 
can then be stored in peripheral tissues such as liver and muscle (62). Lipids 
released from visceral adipose tissue depots directly circulate into the liver via 
the portal vein and give rise to hepatosteatosis (266). The liver also also exhibits 
a high capacity for de novo lipogenesis. This process is mainly regulated by 
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SREBP1c and ChREBP1, which are stimulated by insulin and glucose, 
respectively. Free fatty acids are then esterified into TAG and stored in liver lipid 
droplets or driven into circulation in the form of VLDL (267). Moreover, the liver 
maintains glucose homeostasis by taking up, storing and producing glucose. In 
lean and healthy conditions, hepatic gluconeogenesis (production of glucose) 
and glycogen release (glycogenolysis) are inhibited by insulin. Hepatic 
inflammation and lipotoxicity can contribute to dysregulation of these processes 
is dysregulated (268). Muscle, on the other hand, is the biggest contributor to 
insulin-stimulated glucose uptake and can synthesize glycogen after feeding 
(269, 270). Both liver and muscle are responsive to insulin in the lean state. 
However, in the obese state, elevated lipid metabolites such as fatty acyl co-A, 
diacylglycerol and ceramides can inhibit insulin action by modulating different 
components of the insulin signaling pathway (271). Furthermore, mitochondrial 
dysfunction, endoplasmic reticulum stress, low-grade inflammation and oxidative 
stress can all cause insulin resistance in peripheral tissues in obesity (272). 
Collectively, lack of a peripheral insulin response results in chronic 
hyperglycemia.  Beta cells try to overcome hyperglycemia by producing and 
secreting more insulin, which in turn causes beta cell exhaustion, failure and 
eventually type II diabetes, (Figure 1.4).  Therefore, optimal lipid synthesis and 
storage together with restraining controlled lipolysis in adipose tissue is critical. In 
order to find the novel regulators of these processes and the mechanisms that 
are implicated in the pathogenesis of metabolic diseases, our laboratory 
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performed a microarray study and identified a gene called TNMD as a potential 
candidate.  
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Figure 1.4 
 
 
 
 
 
Figure 1.4: Ectopic lipid deposition and insulin resistance 
Free fatty acids are released into the circulation from dysfunctional adipose 
tissue and stored in the peripheral tissues. Lipotoxicity along with 
proinflammatory cytokines that are secreted from hypertrophic adipocytes and 
activated adipose tissue macrophages leads to insulin resistance in liver and 
skeletal muscle. Hepatic glucose production and glycogen break down can no 
longer be inhibited by insulin in liver and muscle, respectively. Glucose uptake is 
also diminished in these tissues upon insulin resistance, which eventually results 
in beta cell failure and type II diabetes.  
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Tenomodulin (TNMD) and its putative role in metabolism 
 
 Tenomodulin (TNMD) is a 317 aa protein that is encoded by the TNMD 
gene, which is located on the X chromosome and spans approximately 15 kb. 
TNMD was identified by multiple groups as homologous to Chondromodulin-1 
(Chm1) and  predicted to be a type II transmembrane glycoprotein (273-276). 
TNMD has similarities to chondromodulin-1 in both exon and domain 
organization. Moreover, the Cys-rich C-terminal domains of these proteins 
display approximately 33% sequence homology. High TNMD expression was 
demonstrated in dense connective tissues such as tendons; therefore, the 
protein encoded by the TNMD gene was named as “tenomodulin” (275) and has 
been widely used as a tendon and tenocyte differentiation marker (277-279). 
TNMD is composed of three distinct domains. It spans the membrane once; 
therefore, it has a short transmembrane domain, BRICHOS domain and a Cys 
rich C-terminal domain. The BRICHOS domain also exists in other proteins such 
as Chondromodulin-1 and Integral membrane protein 2B (ITM2B or BRI2). The 
exact function of this domain is not fully understood. However, it has been 
suggested to serve as an intra-molecular chaperone for secreted members of 
this family that have an active furin cleavage site (280-282). TNMD has a 
putative furin cleavage motif (R-X-X-R) between amino acids 233-236 (Figure 
1.5) (277).  
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Figure 1.5 
 
 
 
Figure 1.5: Domain structure of tenomodulin 
Tenomodulin is predicted to be a type II transmembrane protein with a 
cytoplasmic N-terminus and extracellular C-terminus. It is composed of a short N-
terminal domain (amino acids 1-30), transmembrane domain (amino acids 31-
51), BRICHOS domain (amino acids 93-186) and Cys-rich C-terminal domain 
with 8 Cys residues (amino acids 255-317). The BRICHOS domain consists of 
two N-glycosylation sites, and a putative furin cleavage site is located between 
amino acids 233-236. 
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 Chondromodulin-1 (Chm-1) is processed and secreted into the 
extracellular matrix by chondrocytes (283, 284). Furthermore, when administered 
into mice, purified chondromodulin-1 inhibited vascularization in cartilage (283). 
Moreover, the secreted portion of chondromodulin-1 inhibited HUVEC cell 
proliferation and tube formation in vitro. When a signal sequence was introduced 
into the TNMD sequence, TNMD was also secreted into media and displayed 
similar effects on HUVEC cells, suggesting that the C-terminal tail of TNMD 
might be cleaved from the putative furin recognition site and be physiologically 
functional (285). TNMD knockout mice, however, did not display any reduced 
vasculature phenotype in tendons.  
 Three isoforms of TNMD have been proposed due to alternative splicing. 
The cellular localization of GFP-tagged isoforms has been analyzed by 
immunofluorescent staining. Isoform I (the most common 7 exon protein) and 
isoform III were detected in the cytoplasm whereas isoform II was mostly 
associated with the nuclear envelope (286). In another study, overexpressed 
TNMD was colocalized with plasma membrane, cytoskeleton and Golgi 
apparatus markers (287). Collectively, these findings suggest that TNMD does 
not solely localize in the plasma membrane, and further studies designed to 
especially detect endogenous levels of TNMD are needed to understand the 
intracellular location of this protein.  
 TNMD was previously predominantly detected in dense connective tissues 
such as tendons, ligaments and cornea (273, 288, 289). However, a 
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comprehensive study demonstrated that adipose tissue has the highest 
expression of TNMD among tissues examined (not including tendons in this 
study) (290). When compared to tendons, however, adipose tissue displayed 
lower TNMD expression (291). Interestingly, TNMD expression in adipose tissue 
correlates with body mass index and increases during obesity in both 
subcutaneous and visceral adipose depots (290). Furthermore, TNMD is one of 
the most responsive genes to weight reduction in human adipose tissue (290, 
292, 293). On the contrary, rat adipose tissue either lacks or has non-detectable 
levels of TNMD expression (291).  
 In a Finnish Diabetes Prevention Study (DPS), SNPs in the TNMD gene 
were associated with some metabolic parameters such as obesity, BMI, and risk 
of diabetes. However, these associations could not be confirmed in a Metabolic 
Syndrome in Men Study (METSIM) study, which had a larger cohort (294-296). 
On the other hand, a BMI-dependent association was found between some 
SNPs in TNMD and serum levels of HDL and LDL (297). Moreover, serum levels 
of some immune mediators such as C-reactive protein, chemokine (C-C motif) 
ligand-5 (CCL-5), CCL-3 and serum amyloid A were associated with SNPs in 
TNMD (298).  
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Scope of this thesis 
 
 The mechanisms by which obesity and adipose tissue dysfunction leads to 
insulin resistance are not fully revealed. Identification of adipocyte specific 
molecules that may protect obese subjects from metabolic syndrome is an 
important approach to understanding these mechanisms as well as developing 
therapeutic approaches for a major health care problem. The aim of the research 
that presented in this thesis is to characterize TNMD as such a molecule. Two 
main questions were addressed here: 
1) Does TNMD play a role in adipocyte differentiation? If so what is the 
mechanism by which TNMD regulate adipogenesis? 
2) Does TNMD affect adipose tissue function? If so, what is its role of 
TNMD in regulating adipocyte specific processes?  
In Chapter II, I present the approach that we took to address these questions. 
Using in vitro cell culture models, I demonstrated that TNMD is required for 
adipocyte differentiation and adipogenic gene expression. Furthermore, in a 
transgenic mouse model, I found that overexpressing TNMD selectively in the 
adipose tissue increased hyperplastic expansion and lipogenic gene expression 
upon HFD feeding. Such healthy adipose tissue expansion leads to attenuated 
liver steatosis and improved systemic insulin resistance. Therefore, TNMD may 
possess therapeutic potential for insulin resistance and type II diabetes.  
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CHAPTER II 
 
TENOMODULIN PROMOTES HUMAN ADIPOCYTE DIFFERENTIATION AND 
BENEFICIAL VISCERAL ADIPOSE TISSUE EXPANSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is derived from the article with the same name published in Nature 
Communications: 
 
Senol-Cosar O., Roth Flach R.J., DiStefano M., Chawla A., Nicoloro S., 
Straubhaar J., Hardy O.T., Noh H.L., Kim J.K., Wabitsch M., Scherer P.E., Czech 
M.P. (2016) 
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Summary 
 
 Proper regulation of energy storage in adipose tissue is crucial for 
maintaining insulin sensitivity, and molecules contributing to this process have 
not been fully revealed. Here, we show that type II transmembrane protein 
tenomodulin (TNMD) is upregulated in adipose tissue of insulin resistant versus 
insulin sensitive individuals who were matched for BMI. TNMD expression 
increases in human preadipocytes during differentiation, whereas silencing 
TNMD blocks adipogenesis. Upon high fat diet feeding, transgenic mice 
overexpressing Tnmd develop increased epididymal adipose tissue (eWAT) 
mass, and preadipocytes derived from Tnmd transgenic mice displayed greater 
proliferation, consistent with elevated adipogenesis. In Tnmd transgenic mice, 
lipogenic genes are were upregulated in eWAT and Ucp1 was upregulated in 
brown fat, while liver triglyceride accumulation was attenuated. Despite 
expanded eWAT, Tnmd transgenic animals display improved systemic insulin 
sensitivity, decreased collagen deposition and inflammation in eWAT as well and 
increased insulin- stimulation stimulated of Akt phosphorylation. Our data 
suggest that TNMD acts as a protective factor in visceral adipose tissue to 
alleviate insulin resistance in obesity. 
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Introduction 
 
 A large body of work has suggested that adipose tissue plays a key role in 
determining metabolic health as a major regulator of carbohydrate and lipid 
homeostasis. Expansion of adipose tissue in overweight or obese humans can 
lead to a spectrum of dysfunctions collectively referred to as metabolic 
syndrome. However, a significant number of metabolically healthy obese human 
subjects demonstrate a situation of benign adipose tissue expansion whose 
differences from pathological obesity are poorly understood (61, 236, 299-301). 
Some studies have suggested that specific physiological mechanisms and 
anatomical locations of adipose expansion may differentially affect metabolic 
homeostasis (302-305). Major white adipose depots located in subcutaneous 
regions and the visceral cavity can dynamically expand during obesity (77). In 
humans, adipose tissue expands via adipocyte hypertrophy during early obesity, 
whereas an increase in adipocyte number, denoted hyperplasia, also occurs in 
prolonged obesity (306, 307). Animal models have demonstrated that 
subcutaneous adipose tissue enlargement is mostly due to hypertrophy while the 
visceral depot expands by increasing both cell size and number upon long term 
high fat diet (HFD) feeding (133, 308). This increase in cell number derives from 
the differentiation of adipocyte precursors into differentiated adipocytes, a well-
defined process that has been extensively modeled in the 3T3-L1 mouse cell line 
(114, 309). Though mouse adipocyte lines such as 3T3-L1 cells have greatly 
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contributed to identifying the molecular mechanisms involved in differentiation 
and maintaining mature adipocyte function (139), interspecies differences in 
gene expression and regulation between mouse and human adipocytes are 
important to consider and further investigate (158, 310).  
 Central obesity is linked to several metabolic morbidities such as type 2 
diabetes and cardiovascular disease (311). Visceral adipose tissue is more prone 
to inflammation than subcutaneous fat in obesity through mechanisms that 
enhance immune cell content (312) and increase pro-inflammatory cytokine 
expression (74, 244, 245, 313). A leading hypothesis suggests that low-grade 
inflammation in fat depots is involved in metabolic syndrome (65, 314). Moreover, 
visceral adipose tissue may be more lipolytic than subcutaneous adipose tissue 
due to dampened insulin suppression of lipolysis and a higher response to 
catecholamines.  This, in turn, increases both non-esterified fatty acid release 
into the circulation and hepatic lipid deposition due to the close proximity of 
visceral adipose tissue to the hepatic portal vein (315, 316). Ectopic lipid storage 
in liver and muscle is thought to trigger insulin resistance in these tissues, 
although not under all conditions (317). Therefore, promoting healthy expansion 
and better lipid storage in visceral adipose tissue is crucial to maintain glucose 
homeostasis and insulin sensitivity.  
 In order to identify and explore mechanisms in adipose tissues that either 
cause insulin resistance or preserve insulin sensitivity in obese individuals, we 
compared gene expression in subcutaneous and omental adipose tissues from 
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obese human subjects matched for body mass index (BMI) but differing in insulin 
resistance. Among several differentially expressed genes identified, we focused 
on tenomodulin (TNMD), a type II transmembrane protein, due to its high and 
predominant expression in human adipose tissue, also noted by others (275, 
290). Comparative analysis of adipose tissue TNMD expression in obese and 
lean individuals also previously indicated that TNMD is strongly correlated with 
BMI (290, 292, 318). Moreover, many genome-wide association studies revealed 
that single nucleotide polymorphisms (SNPs) in the TNMD gene are associated 
with various metabolic characteristics such as BMI, serum low-density lipoprotein 
levels and inflammatory factors (296, 297, 319). Though these studies indicate a 
potential role for TNMD in human adipose tissue, the function of TNMD has not 
been evaluated.  
 Here, by gene silencing and generating a transgenic overexpression 
mouse model, we demonstrate that TNMD is required for adipocyte 
differentiation, and overexpression of Tnmd in adipose tissue protects mice from 
obesity-induced systemic insulin resistance. These data suggest that adipocyte 
TNMD is a protective factor that enhances insulin sensitivity in obesity, potentially 
via promoting hyperplasia and beneficial lipid storage in the visceral adipose 
tissue.  
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Experimental Procedures 
 
Animals 
 All of the studies were approved by The University of Massachusetts 
Medical School Institutional Animal Care and Use Committee. Mice were housed 
in an animal facility with a 12 hour light/dark cycle and had access to water, chow 
or high fat diet (12492i Harlan) ad libitum during the indicated periods. For in vivo 
preadipocyte proliferation studies, mice were treated with 0.8 mg ml-1 BrdU in 
water with 1% sucrose. Water was changed every 72 hours and kept in the dark. 
Mice were euthanized by CO2 and bilateral pneumothorax.  
 
Human samples 
 Human adipose tissue samples collected from morbidly obese patients 
who underwent gastric bypass surgery between 2005 and 2009 at the University 
of Massachusetts Medical School were selected for this study (300). Samples 
used for microarray analysis were from BMI-matched female patients, whereas 
qRT-PCR and Western Blot validations were performed in samples from both 
males and females. Adipose tissue samples were obtained from the lower 
abdominal wall (for subcutaneous) and omentum (for visceral) during the 
surgery. Informed consent was given by the patients, and the study was 
approved by the University of Massachusetts Medical School Institutional Review 
Board. 
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Generation of Adiponectin-Tnmd-Flag transgenic mice 
 Full-length mouse Tnmd with a C-terminal Flag tag was inserted 3’ to 5.4 
kb adiponectin promoter at the Cla I site (320). After verifying both ends by 
sequencing, the transgenic cassette was linearized by Kpn1 and Xho1 digestion, 
purified and submitted for pro-nuclear injection. The transgene was introduced 
into embryos from C57BL/6J mice (000058) (Jackson Laboratories). Embryos 
were then implanted into pseudopregnant C57BL6/J females by the UMASS 
Transgenic Animal Facility. Male transgenic animals were crossed with C57BL6/J 
females. Genotyping was performed by PCR from genomic DNA with the 
following primers: 5’-GACCAGAATGAGCAATGGGTG, 3’-
ATCGTCGTCATCCTTGTAGTCG. 6-8 weeks old Adiponectin-Tnmd-Flag 
transgenic mice and age matched wild-type littermates were used in the 
experiments. Male animals were used unless otherwise was stated.  
 
Western Blotting 
 Cell lysates were prepared using RIPA buffer (150 mM NaCl, 50 mM Tris 
pH 7.4, 1% sodium deoxycholate, 1% NP-40, 0.2 % SDS, 50 mM EDTA) 
containing 1X HALT protease and phosphatase inhibitors (Thermo Scientific). 
Total protein was separated on SDS-PAGE gels and transferred to nitrocellulose 
membranes. Membranes were blocked with 5% milk solution in TBS-T and 
immunoblotted with an antibody generated against NGIEFDPMLDERGYC 
peptide from C-terminus of TNMD (Rockland, 1:5000) and antibodies against 
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C/EBPα (8178), C/EBPβ (3082), PPARγ (2443), phospho AKT(S308) (9275), 
phospho AKT(T473) (4060), total AKT (4691 or 2920), ACLY (4332), ACC 
(3662), PLIN (3470), (Cell Signaling, 1:1000), FASN (BD Biosciences, 610963, 
1:2000), FLAG (F7425, 1:2000) tubulin and actin (Sigma, 1:5000).  
 
qRT-PCR analysis 
 Total RNA was isolated using TriPure (Roche) according to the 
manufacturer’s protocol. DNAse (DNA-free, Life Technologies)-treated RNA was 
reverse transcribed into cDNA using iScript (BioRad). Quantitative PCR analyses 
were performed using SYBR green (iQ SYBR Green Supermix, BioRad) on 
BioRad CFX97. Primer sequences used for qRT-PCR analyses were listed in 
Table 2.1. HUGO Gene Nomenclature Committee’s Guideline was used for gene 
names written in this thesis.  
 
Accession Codes 
 Microarray data have been deposited in GEO database under accession 
code GSE76319 and GSE20950.  
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Table 2.1 
Human Primers 
Gene Forward Reverse 
TNMD ATTCAGAAGCGGAAATGGCACTGA TAGGCTTTTCTGCTGGGACCCAA 
C/EBPA CAAGAACAGCAACGAGTACCG GTCACTGGTCAGCTCCAGCAC 
PPARG2 CTCCTATTGACCCAGAAAGCGA TGCCATGAGGGAGTTGGAAG 
PLIN1 GACCTCCCTGAGCAGGAGAAT GTGGGCTTCCTTAGTGCTGG 
KLF4 GATGAACTGACCAGGCACTA TCGGGAAGACAGTGTGAAAA 
SPP1 CTCCATTGACTCGAACGACTC CAGGTCTGCGAAACTTCTTAGAT 
ADIPOQ TCTGCCTTCCGCAGTGTAGG GGTGTGGCTTGGGGATACGA 
RPLP0 CAGATTGGCTACCCAACTGTT GGGAAGGTGTAATCCGTCTCC 
 
 
Mouse Primers 
Gene Forward Reverse 
Tnmd AATGGGTGGTCCCGCAAGTG ACAGACACGGCGGCAGTAAC 
C/ebpa CAAGAACAGCAACGAGTACCG GTCACTGGTCAGCTCCAGCAC 
C/ebpb GCAAGAGCCGCGACAAG GGCTCGGGCAGCTGCTT 
Pparg2 TCGCTGATGCACTGCCTATG GAGAGGTCCACAGAGCTGATT 
Cidec ATCAGAACAGCGCAAGAAGA CAGCTTGTACAGGTCGAAGG 
Lept GAGACCCCTGTGTCGGTTC CTGCGTGTGTGAAATGTCATTG 
Adipoq TGTTCCTCTTAATCCTGCCCA CCAACCTGCACAAGTTCCCTT 
Glut4 GTGACTGGAACACTGGTCCTA CCAGCCACGTTGCATTGTAG 
Plin1 CTGTGTGCAATGCCTATGAGA CTGGAGGGTATTGAAGAGCCG 
Srebp1c GGCCCGGGAAGTCACTGT GGAGCCATGGATTGCACATT 
Fasn GGAGGTGGTGATAGCCGGTAT TGGGTAATCCATAGAGCCCAG 
Acly ACCCTTTCACTGGGGATCACA GACAGGGATCAGGATTTCCTTG 
Acc1 TGTACAAGCAGTGTGGGCTGGCT CCACATGGCCTGGCTTGGAGGG 
Cd68 CCATCCTTCACGATGACACCT GGCAGGGTTATGAGTGACAGTT 
Ccl2 GCTGGAGAGCTACAAGAGGATCACC TCCTTCTTGGGGTCAGCACAGAC 
Il-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Tnfa CCCTCACACTCAGATCATCTTCT GTCACGACGTGGGCTACAG 
Ucp1 ACTGCCACACCTCCAGTCATT CTTTGCCTCACTCAGGATTGG 
Prdm16 CCAAGGCAAGGGCGAAGA AGTCTGGTGGGATTGGAATGT 
Plin2 GACCTTGTGTCCTCCGCTTAT CAACCGCAATTTGTGGCTC 
Mmp2 AACACTGAAGATCTTGCTCTGAGAT TTGAGAGACTGAGACAGGGAGTC 
Mmp3 TGATGAACGATGGACAGAGG GAGAGATGGAAACGGGACAA 
Mmp9 ACCACATCGAACTTCGA CGACCATACAGATACTG 
Mmp12 CTGGACAACTCAACTCT AGAGGAGTCACATCACT 
Mmp14 CAGTATGGCTACCTACCTCCAG GCCTTGCCTGTCACTTGTAAA 
Fn1 ATGTGGACCCCTCCTGATAGT GCCCAGTGATTTCAGCAAAGG 
Smad2 ATGTCGTCCATCTTGCCATTC AACCGTCCTGTTTTCTTTAGCTT 
Smad3 CACGCAGAACGTGAACACC GGCAGTAGATAACGTGAGGGA 
Cola1a1 GCTCCTCTTAGGGGCCACT CCACGTCTCACCATTGGGG 
Col5a1 CTTCGCCGCTACTCCTGTTC CCCTGAGGGCAAATTGTGAAAA 
Col6a1 AACAGGAATAGGAAATGTGACCC ACACCACGGATAGGTTAGGGG 
Col6a3 CAGAACCATTGTTTCTCACT AGGACTACACATCTTTTCAC 
Tgfb1 ATTCCTGGCGTTACCTTGG AGCCCTGTATTCCGTCTCCT 
Vwf CTTCTGTACGCCTCAGCTATG GCCGTTGTAATTCCCACACAAG 
Cd31 ACGCTGGTGCTCTATGCAAG TCAGTTGCTGCCCATTCATCA 
Cdh5 CACTGCTTTGGGAGCCTTC GGGGCAGCGATTCATTTTTCT 
Thbs1 GGGGAGATAACGGTGTGTTTG  CGGGGATCAGGTTGGCATT  
36b4 TCCAGGCTTTGGGCATCA CTTTATCAGCTGCACATCACTCAGA 
  
Table 2.1: Primer sequences used in the qRT-PCR analyses  
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Cell culture  
 Simpson Golabi Behmel Syndrome (SGBS) cells were obtained from Dr. 
Martin Wabitsch’s laboratory and cultured in DMEM/F12 media supplemented 
with 10% fetal bovine serum, 33 uM biotin, 17 uM pantothenic acid, 100 units ml-1 
penicillin and 0.1 mg ml-1 streptomycin until full confluence. Cells were washed 
with PBS before differentiation, and differentiation was stimulated with serum-
free media containing rosiglitazone, dexamethasone, 3-isobutyl-1-
methylxanthine, cortisol, transferrin, triiodothyronine, and human insulin. 4 days 
later, the differentiation cocktail was replaced with adipocyte maintenance media 
(DMEM/F12, biotin, pantothenic acid, transferrin, insulin and cortisol). Cells were 
maintained until they are fully differentiated (day 14). 3T3-L1 preadipocytes were 
obtained from AATC (CL-173). Cells were cultured in high glucose DMEM media 
supplemented with 10% FBS, 50 µg ml-1 streptomycin, and 50 units ml-1 penicillin 
and differentiated into adipocytes with high glucose DMEM media with 10% FBS, 
50 µg ml-1 streptomycin, 50 units ml-1 penicillin, 5 µg ml-1 insulin, 0.25 µM 
dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine.  
 
Oil Red O Staining  
 Differentiated adipocytes were fixed with 10% formalin, washed with 60% 
isopropanol and air dried. Oil Red O working solution was added on cells and 
washed with distilled water to remove excess dye. Oil Red O was extracted using 
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100% isopropanol and absorbance was measured in 520 nm in spectrometer for 
quantification.  
 
siRNA transfection of SGBS and 3T3-L1 preadipocytes 
 SGBS or 3T3-L1 preadipocytes were plated into 12-well plates (105 cells 
per well) and transfected with 100 nM (SGBS) or 50 nM (3T3-L1) scrambled 
siRNA or TNMD siRNA (Dharmacon, siGENOME, Smartpool) using 
Lipofectamine RNAiMax (Life Technologies) according to the manufacturer’s 
protocol. 48 hours after transfection, cells were harvested or stimulated for 
adipogenesis.  
  
MTT assay 
 SGBS preadipocytes (104 cells per well) were plated in 96 well plates. 24 
hours later, they were transfected with either scrambled or TNMD siRNA. Cell 
viability was measured 0, 24 and 48 hours after transfection using an MTT assay 
kit (Biotium Inc.) according to the manufacturer’s instructions.  
 
Immunofluorescence staining  
 Differentiated adipocytes were fixed with 10% formalin and permeabilized 
in 0.1% Triton X in PBS. 3% BSA in PBS was used for blocking. Cells were 
incubated overnight with PLIN antibody (Cell Signaling) diluted in 1% BSA 
solution and 45 minutes at 37 0C with secondary antibody (Alexa Fluor 488, Life 
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Technologies). Nuclei were stained with DAPI.  Preadipocytes were fixed in 70% 
cold methanol and treated with 1.5 M HCl for 30 min. After washing, they were 
washed and blocked with 5% normal goat serum and 0.3% Triton-X100 in PBS. 
Primary antibodies for BrdU and Pref1 (Cell Signaling 5292, 1:1000 and EMD 
Millipore, AB3511, 1:100) were applied overnight. Cells were washed and 
incubated with secondary antibodies for 90 min at room temperature and 
mounted with Prolong® Gold Antifade Reagent with DAPI. Images from at least 3 
different areas were taken, and nuclei were counted by Image J Analysis 
Software. For vessel density in adipose tissue, whole-mount staining was 
performed after 10% formalin fixation. Tissues were blocked overnight in 10% 
BSA and 0.3% triton X-100 in PBS at 4 0C, stained overnight with Isolectin B4 
(Life Technologies I21411; 1:40) in 100 mM MgCl2, 100 mM CaCl2, 10 mM 
MnCl2, and 1%Triton X-100 in PBS at 4 0C, and washed 3x 20 minutes in 5% 
BSA, 0.15% triton X-100 in PBS at room temperature. Approximately 1 mm 
cubes were whole-mounted in ProLong Gold (Life Technologies). Images were 
visualized in flattened 25 um z-stacks with confocal microscopy at 10x. Images 
were acquired with MetaMorph Software, version 6.1 (Universal Imaging, 
Downingtown, PA). At least 3 technical replicates of adipose tissue images were 
quantified per mouse and averaged for average vascular density. Images were 
quantified using Image J Analysis Software. 
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Histology 
 Tissue samples were fixed in 10% formalin and embedded in paraffin. 
Sectioned slides were then stained with hematoxylin and eosin by the UMass 
Medical School Morphology Core. Adipocyte size was assessed using Adiposoft 
software (321). 
 
Insulin and Glucose tolerance tests 
 Mice fed with the indicated diets were fasted 16 hours for glucose 
tolerance tests and or 4 hours for insulin tolerance tests. Basal blood glucose 
levels were measured with a Breeze-2-glucose meter (Bayer) before and after 
they were intraperitoneally injected with glucose (1 g kg-1) or insulin (1IU kg-1).  
 
Hyperinsulinemic-euglycemic clamp and metabolic cage studies 
 The clamp and metabolic cage studies were performed at the UMass 
Mouse Metabolic Phenotyping Center. Mice fed with HFD for 12 weeks were 
subjected to a 4-hour fast, and a 2-h hyperinsulinemic-euglycemic clamp was 
performed with a primed and continuous infusion of human insulin (150 mU kg-1 
body weight priming followed by 2.5 mU kg-1 min-1; Humulin, Eli Lilly). During the 
clamp, 20% glucose was infused at variable rates to maintain euglycemia (322). 
Whole body glucose turnover was assessed with a continuous infusion of [3-3H] 
glucose, and 2-deoxy-D-[1-14C]glucose (PerkinElmer, Waltham, MA) was 
administered (10 µCi) at 75 min after the start of clamps to measure insulin-
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stimulated glucose uptake in individual organs. At the end of the study, mice 
were anesthetized, and tissues were taken for biochemical analysis. The 
metabolic cages were used to measure food intake, respiratory exchange ratio, 
VO2 consumption and physical activity over a 3-day period, and average for each 
parameter was calculated (TSE Systems).  
 
Plasma analysis 
 Blood samples collected from animals after a 16-hour fast via cardiac 
puncture. Serum triglyceride levels were measured using a Serum Triglyceride 
Determination Kit (Sigma). Free fatty acid and total cholesterol in plasma 
samples were analyzed using NEFA (Free Fatty Acid) Kit (Wako Diagnostics) 
and Cholesterol/Cholesteryl Ester Quantitation Kit (Abcam) respectively.  
 
Ex vivo lipogenesis assay 
 Adipose tissue explants were incubated with labeling media containing 
2.50% FA free BSA, 1% (v/v) Pen/Strep, 0.5 mM d-Glucose, 2 mM sodium 
pyruvate, 2 mM glutamine, 2 µCi mL-1 [14C]-U-glucose. Insulin (1 µM) was added 
to insulin-stimulated conditions and incubated for 4.5 h before lipid extraction at 
37 °C. The reaction was stopped by adding modified Dole's extraction mixture 
(80 mL isopropanol, 20 mL hexane, 2 mL of 1N H2SO4). Total triglyceride was 
extracted with hexane, washed and evaporated and counted by liquid scintillation 
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Ex vivo lipolysis assay 
 Adipose tissue explants were isolated from iWAT and eWAT of mice that 
had been fed chow diet for 12 weeks. Fat pads were measured, and a 30 mg 
piece was placed in freshly prepared KRH buffer (125 mM NaCl, 5 mM KCl, 1.8 
mM CaCl2, 2.6 mM MgSO4, 5 mM HEPES, pH 7.2) containing 2.5% BSA (fatty 
acid free) and 1 mM sodium pyruvate until stimulation. Subsequently, extracts 
were treated with PBS or isoproterenol (10 µM) for 2 h at 37°C. Free glycerol 
content in the buffer was quantified for each sample using the Free Glycerol 
Determination Kit (Sigma). Glycerol release from each sample was normalized to 
the weight of each fat pad. 
 
Statistical Analysis 
 A two-tailed Student’s t-test with Welch’s correction was performed to 
analyze the difference between two groups using Microsoft Excel or Graph Pad 
Prism 6.0. The Grubb’s test was used to determine the statistical outliers. In case 
of an outlier was determined, it was removed from the statistical analysis. 
Experimental data were represented as the mean of at least three biological 
replicates. P values < 0.05 were considered to be statistically significant. 
Variance was estimated using the standard error of the mean for both groups 
that were statistically compared. No statistical methods were used to predict 
sample size. No randomization or blinding was performed to allocate the samples 
for animal experiments.  
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Results 
 
Higher expression of human TNMD in insulin resistance 
 To assess gene expression differences in insulin resistant vs. insulin 
sensitive obese individuals, total RNA was isolated from snap frozen adipose 
tissue biopsies from omental and subcutaneous fat depots of human subjects 
undergoing bariatric surgery, and analyzed for genome-wide gene expressions. 
Clinical data of the subjects used in gene expression analysis are shown in Table 
2.2. DNA microarray data identified TNMD as a gene that is significantly 
upregulated in omental fat from insulin-resistant individuals compared with BMI-
matched, insulin sensitive subjects (Figure 2.1, a). However, no significant 
difference in TNMD gene expression was observed between the two groups in 
subcutaneous adipose tissue (Figure 2.1, b). These results were validated by 
assessing mRNA and protein levels using qRT-PCR and Western blotting 
respectively (Figure 2.1, c-d).  
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Table 2.2 
 
 
Insulin Sensitive 
(n=8) 
(Mean±SE) 
Insulin Resistant 
(n=6) 
(Mean±SE) P 
Age 37 (±1.57) 44 (±3.72) 0.1060 
Weight 295.875 (±14.89) 317.17 (±22.38) 0.4257 
BMI 48.25 (±1.04) 50 (±3.34) 0.5829 
EBW 167.25 (±11.15) 182.67 (±21.05) 0.5006 
Fasting glucose (mg/dl) 88.125 (±3.28) 104.83(±5.20) 0.0145 
Fasting insulin (mIU/l) 9.375 (±1.54) 24 (±3.72) 0.0017 
HOMA-IR (mmol/l) 1.375 (±0.22) 3.57 (±0.53) 0.0013 
%B Beta cell sensitivity 125.4 (±18.47) 174.12 (±25.89) 0.1405 
 
Table 2.2: Clinical characteristics of subjects selected for human 
Affymetrix GeneChip analysis. 
BMI: Body-Mass Index  
EBW: Excess body weight 
HOMA-IR: homeostasis model assessment of insulin resistance 
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 It was previously demonstrated that white adipose tissue and primary 
adipocytes have the highest expression of TNMD among human tissues (290). 
Although this original study claimed similar TNMD expression in the stromal 
vascular fraction (SVF) and whole adipose tissue, we observed that TNMD is 
predominantly expressed in adipocytes compared with cells from the SVF in both 
visceral and subcutaneous white adipose tissues (Figure 2.2, a,b). SPP1 and 
PLIN1 were used as specific markers for SVF and primary adipocytes, 
respectively (Figure 2.2, c,d).  
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 To assess the role of TNMD in human adipocyte function, we utilized 
human preadipocytes obtained from a subject with Simpson-Golabi-Behmel 
Syndrome (SGBS cells) (148) and discovered that TNMD expression increased 
by several hundred fold during adipocyte differentiation in culture (Figure 2.3, a). 
Expression of mature adipocyte markers such as PPARG2 and ADIPOQ certified 
that these cells had undergone adipocyte differentiation after induction with the 
adipogenic cocktail. TNMD expression was increased even 18 hours after 
stimulation of the preadipocytes. Moreover, TNMD exhibited a time-dependent 
expression profile similar to peroxisome proliferator-activated receptor gamma 2 
(PPARG2) and CCAAT/enhancer-binding protein alpha (C/EBPA), but not 
Kruppel-like factor 4 (KLF4), which is an early transcription factor in the 
adipogenic cascade (Figure 2.3, b).  
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TNMD is required for human adipogenesis 
 Several studies have demonstrated that adipose tissue expansion in 
obesity is promoted by adipogenesis in addition to adipocyte hypertrophy in both 
mice and humans (133, 220, 323-325). Because TNMD had an expression 
profile that was similar to genes that are critically involved in adipocyte 
differentiation and its expression is increased in obese adipose tissue, we 
hypothesized that TNMD might be involved in human adipocyte differentiation. 
To test this hypothesis, TNMD was silenced in SGBS preadipocytes two days 
prior to adipogenic stimulation (Figure 2.4, a). Remarkably, silencing of TNMD 
significantly attenuated differentiation as demonstrated by substantially 
decreased accumulation of neutral lipids measured by Oil Red O staining at day 
14 (Figure 2.4, b,c). Analysis of mature SGBS adipocytes also revealed that 
preadipocytes lacking TNMD had fewer lipid droplets and lacked a differentiated 
adipocyte morphology as assessed by perilipin (PLIN) staining (Figure 2.4, d). 
Thus, TNMD is required for human adipocyte differentiation. To further 
investigate whether TNMD is required for adipogenic gene expression during 
differentiation, total mRNA was isolated at different time points of differentiation 
(Fig. 2a), and expression of adipogenic markers such as PLIN1, C/EBPA, and 
PPARG2 were analyzed by qRT-PCR. Indeed, expression of these genes was 
significantly blunted at most of the majority of time points in TNMD silenced cells 
compared with cells that had been transfected with scrambled siRNA (Figure 2.4, 
e). 
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Figure 2.4: siRNA mediated silencing of TNMD attenuates differentiation in 
human adipocytes 
SGBS preadipocytes were transfected with siRNA two days prior to adipogenesis 
induction. Total RNA isolation and Oil Red O staining were performed on the 
stated days of differentiation. (a) Schematic demonstration of experimental 
method. (b,c) Adipocytes were differentiated for 14 days in culture and stained 
with Oil Red O. (b) Representative images (Scale bars represent 100 µm). (c) 
Quantification of Oil Red O staining (mean±SEM; n=4  *p<0.05, Student’s t-test). 
(d) Immunofluorescent staining of mature adipocytes with PLIN (green) and DAPI 
(blue) (Scale bars represent 20 µm). (e) Quantitative PCR analysis of TNMD, 
C/EBPA, PPARG2 and PLIN1 expression at days 0, 4, 8 and 12 of adipocyte 
differentiation in SGBS cells (mean±SEM; n=3 *p<0.05, **p<0.01, ***p<0.001). 
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 Although TNMD expression is low in murine adipocytes, TNMD depletion 
in 3T3-L1 preadipocytes revealed that TNMD is also required for mouse 
adipocyte differentiation and plays a similar role to regulate adipogenic gene 
expression as in SGBS cells (Figure 2.5, a,b). These data suggest that even 
though expression profiles are different between mature human and mouse 
adipocytes, the requirement of TNMD for differentiation is conserved between the 
two species.  
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 Unlike the mouse cell line 3T3-L1, human primary adipocytes do not 
undergo clonal expansion (326, 327). SGBS cells also did not display any 
increase in cell number during the first five days of differentiation (Figure 2.6, a), 
suggesting that clonal expansion also does not occur in these cells. Therefore, 
full confluence is important for SGBS cells to differentiate. To assess whether 
TNMD affected cell death in SGBS preadipocytes, an MTT (3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) cell viability assay was 
performed to assess viability in TNMD-silenced SGBS cells. The results show 
that siRNA-mediated silencing of TNMD did not affect the viability in these cells  
(Figure 2.6, b).  
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 Because the expression of adipogenic transcription factors increases 
dramatically even during the first day of differentiation, we asked whether TNMD 
silencing diminishes the early induction of these transcription factors as well as 
their target genes. Thus, a DNA microarray analysis was performed in SGBS 
cells that had been transfected with either scrambled or TNMD siRNA at day 1 of 
differentiation. The induction of many adipogenic genes was significantly 
diminished after TNMD depletion (Figure 2.7, a, b). Importantly, in the absence of 
TNMD, stimulation of both the early transcription factor CCAAT/enhancer-binding 
protein beta (C/EBPβ) as well as late transcription factors C/EBPα and PPARγ 
were diminished (Figure 2.8, a, b).  
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 The C-terminal domain of TNMD is similar to the secreted and functional 
portion of its homologous protein Chondromodulin 1 (CHM1) (275), and studies 
have suggested that the C-terminal domain of TNMD is functionally active (285). 
We sought to understand whether the effect of TNMD to regulate adipogenesis is 
cell autonomous. Thus, SGBS cells treated with siTNMD were mixed with non–
transfected cells in equal numbers to determine whether wild-type TNMD 
rescues the adipogenic defect in TNMD-silenced cells via a paracrine 
mechanism. After adipogenic stimulation, we observed that Oil Red -O staining 
was diminished by approximately 50% when control cells were co-cultured with 
transfected cells, suggesting that the adipogenic effect of TNMD is cell 
autonomous in vitro (Figure 2.9, a).  
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Figure 2.9 
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Figure 2.9: Co-culture of non-transfected SGBS preadipocytes with TNMD 
transfected cells. (a) SGBS preadipocytes were transfected with either 
Scrambled or siTNMD. 24 hours after transfection, cells were trypsinized and 
seeded in equal numbers from stated groups in a different well. 2 days after 
transfection, cells were stimulated with adipogenic cocktail. Adipogenesis was 
analyzed by Oil Red O staining and microscopy. The data are representative of 
two independent experiments. The scale bar represents 100um. 
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Increased eWAT expansion in Tnmd overexpressing mice 
 To gain a better understanding of the role of Tnmd in adipose tissue, we 
generated transgenic mice that overexpress mouse Tnmd under the adipose 
tissue-specific Adiponectin promoter (Figure 2.10, a). A transgenic line that 
exhibited significant overexpression of Tnmd in inguinal (iWAT), epididymal 
(eWAT) and brown adipose tissue (BAT) were utilized in these experiments. 
qRT-PCR and Western Blot analysis demonstrated that Tnmd expression was 
specific to adipose tissue in these mice (Figure 2.10, b,c).  
 Given that TNMD expression is increased during obesity in human 
adipose tissue (290), weight gain was assessed in the Tnmd transgenic mice, 
and no weight difference was observed compared with littermate controls after 
both chow and high fat diet (HFD) fed conditions (Figure 2.11, a). However, a 
significant increase in eWAT weight was observed in HFD-fed but not in chow-
fed transgenic animals (Figure 2.11, b). The transgenic mice also displayed a 
concomitant decrease in liver weight after HFD, suggesting that the Tnmd 
transgenic mice may have enhanced adipose tissue storage capacity, which may 
attenuate lipid deposition in non-adipose tissues. Transgenic mice also had 
significantly smaller brown adipose tissue when compared with controls. 
However, no significant difference was detected in inguinal and axillary white 
adipose tissue weights after either feeding regimens (Figure 2.11, b).  
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TNMD promotes healthy visceral adipose tissue expansion 
 Because Tnmd transgenic mice had larger eWAT (Figure 2.11, b) and 
because TNMD is required for adipogenesis (Figure 2.4), white adipose tissue 
cell size was assessed to understand whether the significant increase in eWAT 
weight in Tnmd transgenic mice was due to hypertrophy or hyperplasia. Though 
the eWAT pads were larger, no significant difference in adipocyte size was 
observed in eWAT or iWAT depots of HFD-fed Tnmd transgenic mice (Figure 
2.12, a,b), and this was also the case after a short term (4-week) HFD (Figure 
2.12, c,d,e). These results suggest that the increased eWAT weight (Figure 2.11, 
b) was caused by an increase in adipocyte number rather than hypertrophy.  
We thus investigated whether preadipocyte proliferation was affected in TNMD 
transgenic mice. Recently, Jeffery et al. demonstrated that there is a significant 
increase in preadipocyte proliferation during first week of HFD in visceral adipose 
tissue (220). To assess preadipocyte proliferation in vivo, we treated control and 
Tnmd transgenic mice with BrdU for one week in their drinking water and 
concurrently fed them HFD for 6 days (Figure 2.13, a). Preadipocytes were then 
isolated, seeded on coverslips and media selected for 24 hours followed by 
immunostaining for BrdU and Pref1 as a preadipocyte marker. Remarkably, a 
significant increase in BrdU incorporation was observed in preadipocytes that 
were isolated from the eWAT of Tnmd transgenic mice (Figure 2.13, b,c). These 
data suggest that TNMD promotes eWAT expansion by enhancing preadipocyte 
proliferation in response to HFD.  
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Figure 2.12: Assesment of iWAT and eWAT depots at 4 and 16 weeks of 
HFD in control and transgenic mice  
6 week-s old male control (Ctrl) and Tnmd transgenic (Tg) animals were fed HFD 
for either 4 or 6 weeks (a) Representative H&E images of eWAT and iWAT (n=5 
(control), n=9 (transgenic), Scale bars represent 100 µm). (b) Adipocyte size was 
analyzed using Adiposoft software. At least 4 different areas per mouse were 
analyzed, and the average adipocyte size in each group was calculated 
(mean±SEM; n=5 (control), n=9 (transgenic), Student’s t-test). (c) Epididymal 
and inguinal white adipose tissue weights measured after 4 weeks of HFD in 
control (Ctrl) and transgenic (Tg) animals and normalized to total body weights 
(mean±SEM; n=8 (control), n=5 (transgenic), Student’s t-test) (d) Histologic 
analysis of eWAT and liver of from transgenic (Tg) and control (Ctrl) mice after 4 
weeks. Scale bars represent 100 µm (e) Adipocyte size was analyzed and 
avarage average adipocyte size was calculated for each group (mean±SEM; n=8 
(control), n=5 (transgenic), Student’s t-test). 
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 Consistent with these results, mRNA levels encoding adipogenic and 
lipogenic genes Plin1, sterol regulatory element-binding protein 1c (Srebp1c), 
fatty acid synthase (Fasn) and ATP-citrate lyase (Acly) were significantly 
increased, and the protein levels of PPARγ, PLIN, FASN, ACLY were 1.5-1.9 fold 
increased in Tnmd transgenic mouse visceral adipose tissue (Figure 2.14, a-c). 
These observations suggest that overexpressing Tnmd in visceral adipose tissue 
increases its storage capacity by both increasing adipocyte number and 
upregulating lipogenesis. Although no difference in [14C]-Glucose incorporation 
into triglyceride was observed in adipose tissue explants that had been isolated 
from chow-fed control and TNMD transgenic animals (Figure 2.14, d), such 
assays performed in vitro are quite artificial and may not represent physiological 
conditions.   
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Figure 2.14: Increased lipogenic gene expression in Tnmd transgenic mice 
(a) Quantitative PCR (mean±SEM; n=9 (control), n=11 (transgenic) and (b,c) 
Western blot analysis of adipogenic and lipogenic genes in eWAT of HFD-fed 
male animals and quantification of blots (mean±SEM; n=5 (control), n=9 
(transgenic)  *p<0.05, **p<0.01 by Student’s t-test) (d) Ex vivo lipogenesis 
analysis in adipose depots in transgenic and control mice. Insulin stimulated 
[14C]-Glucose incorporation into triglyceride was measured in adipose tissue 
explants that had been isolated from 12 weeks chow fed mice (mean±SEM; n=4, 
Student’s t-test).  
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Tnmd mice displayed reduced inflammation and tissue fibrosis in eWAT 
 A previous report suggested that TNMD has antiangiogenic properties in 
cultured endothelial cells (285). However, TNMD knockout mice did not display 
any obvious vascular abnormalities (277). These previous studies suggested that 
TNMD might have effects on blood vessel density or extracellular matrix 
composition. Blood vessel morphology and density was assessed in HFD-fed 
control and TNMD transgenic mice; however, no differences were observed 
(Figure 2.15, a). Furthermore, endothelial cell marker gene expression was 
unaltered in TNMD transgenic adipose tissue as assessed by qRT-PCR (Figure 
2.15, b).  
 Interestingly, a previous report characterizing TNMD-null mice noted 
disorganized collagen fibrils (277); thus, we hypothesized that TNMD might be 
involved in ECM processing. Trichrome staining was performed in control and 
TNMD transgenic mice to investigate whether TNMD is involved in regulating 
extracellular matrix and tissue fibrosis in eWAT. Remarkably, whereas abundant 
blue collagen staining was observed in eWAT of control mice, collagen 
accumulation was clearly decreased in transgenic mice, even in the inflamed 
areas (Figure 2.15, c). Moreover, gene expression analysis of whole adipose 
tissue revealed that genes encoding ECM proteins such as Col1a1, Mmp12, 
Mmp14 as well as genes involved in TGFβ signaling were significantly decreased 
in transgenic eWAT compared to control animals suggesting that TNMD might be 
involved in regulating extracellular matrix composition (Figure 2.15, d). Therefore, 
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TNMD may promote healthy visceral adipose tissue expansion through a direct 
interaction with ECM proteins and regulation of ECM remodeling.  
 Many studies have demonstrated that inflammation, immune cell 
infiltration and expansion occur in visceral adipose tissue during obesity, which is 
associated with metabolic dysfunction and insulin resistance (64, 244, 245, 300, 
312, 328, 329). After prolonged HFD, immune cell infiltration was increased in 
eWAT of control mice, whereas transgenic mice displayed fewer crown-like 
structures by histological analysis (Figure 2.12, a; Figure 2.15, c). Furthermore, 
qRT-PCR results demonstrated that macrophage marker Cd68 and macrophage-
derived cytokines such as monocyte chemotactic protein 1 (Ccl2) were 
downregulated by 40% in transgenic mice (Figure 2.15, e). Thus, Tnmd 
overexpression also promotes adipose tissue integrity by preventing adipose 
tissue inflammation in obesity. 
 
 
 
 
 
 
 
 
 
85
 
 
 
 
 
Figure 2.15: Decreased inflammation and collagen expression in eWAT of 
Tnmd transgenic mice 
(a) Isolectin staining and vessel density quantification in eWAT from control and 
transgenic animals fed with HFD for 8 weeks of HFD (mean±SEM; n=5 for both 
control and transgenics, *p<0.05, **p<0.01, by Student’s t-test.) Scale bars 
represent 100 µm. (b) Quantitative PCR for angiogenesis markers in eWAT from 
16 weeks HFD fed control and transgenic mice (mean±SEM; n=9 (control), n=11 
(transgenic), *p<0.05, **p<0.01, by Student’s t-test). (c) Representative images 
of Trichrome staining in eWAT from control (Ctrl) and transgenic (Tg) mice that 
had been fed HFD for 16 weeks. Scale bars represent 400 µm (left panel), 100 
µm (middle panel), 50 µm (right panel). (d) Quantitative PCR of ECM and TGFβ 
signaling genes in eWAT from HFD-fed animals (mean±SEM; n=9 (control), n=10 
(transgenic), *p<0.05, **p<0.01, by Student’s t-test). (e) qRT-PCR analysis of 
inflammatory genes in eWAT from HFD-fed animals (mean±SEM; n=9 (control), 
n=11 (transgenic), *p<0.05, **p<0.01, by Student’s t-test). 
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TNMD inhibited lipid deposition in liver and BAT 
 Consistent with our observation that the Tnmd transgenic mouse BAT 
depot was smaller, we observed fewer lipid droplets in histological samples of 
BAT histological sections (Figure 2.16, a). Importantly, brown adipocyte markers 
such as uncoupling protein 1 (Ucp1) and PR domain containing 16 (Prdm16) 
were significantly increased by nearly 2-fold in transgenic mouse BAT compared 
with that from controls upon HFD challenge (Figure 2.16, b). These results 
suggested that Tnmd overexpression in BAT may also promote BAT 
maintenance of mitochondrial fatty acid oxidation during HFD and contribute to 
overall beneficial metabolism. However, metabolic cage analysis in HFD-fed 
TNMD transgenic and control mice with similar food intake and physical activity 
revealed no significant differences in respiratory exchange ratio (RER) or VO2 
consumption (Figure 2.16, c-f).  
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Figure 2.16: Lipid deposition in BAT was decreased in transgenic mice 
a) Representative histological analysis of BAT from HFD-fed animals. Scale bars 
represent 100 µm. (b) Quantitative PCR analysis of Ucp1, Prdm16, Pparg2, 
C/ebpa and C/ebpb in BAT of HFD-fed animals (mean±SEM; n=9 (control), n=11 
(transgenic), *p<0.05, **p<0.01, ***p<0.001, by Student’s t-test). (c-f) Metabolic 
cage analysis was performed in male mice that had been fed with HFD for 12 
weeks. (c) Average food intake per mouse during the day (7am-7pm) and night 
(7pm-7am) over 3 days (mean±SEM; n=8 (control), n=5 (transgenic)). (d) 
Physical activity was calculated as average of total movements per mouse during 
the day (7am-7pm) and night (7pm-7am) over 3 days (mean±SEM; n=8 (control), 
n=5 (transgenic)). Average (e) VO2 consumption and (f) Respiratory Exchange 
Ratio during the day (7am-7pm) and night (7pm-7am) over 3 days (mean±SEM; 
n=8 (control), n=5 (transgenic)). 
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 A significant decrease in liver weight was also observed in Tnmd 
transgenic mice compared with their control littermates (Figure 2.11, b). 
Therefore, we assessed hepatic lipid content in HFD-fed mice by both 
histological and triglyceride (TG) analysis. Although hepatic TG content 
increased by 2-fold in control animals fed HFD, strikingly, Tnmd transgenic 
animals displayed no HFD-induced increase in hepatic TG content and instead 
displayed a 60% reduction compared with control HFD-fed littermates (Figure 
2.17, a,b). Consistent with the decreased lipid content of livers in the HFD-
challenged transgenic animals, hepatic genes involved in lipid droplet formation 
that are associated with fatty liver such as perilipin 2 (Plin2) and cell death-
inducing DFFA-like effector c (Cidec) were significantly downregulated in HFD-
fed Tnmd transgenic mice (Figure 2.17, c).  
 Assessment of serum metabolic parameters demonstrated that HFD-fed 
Tnmd transgenic animals had significantly less total plasma cholesterol levels. 
However, no differences were detected in triglyceride levels on chow or HFD 
(Figure 2.17, d, e). Furthermore, serum free fatty acid levels were significantly 
reduced in chow-fed Tnmd transgenic animals (Figure 2.17, f). However, though 
serum fatty acid levels can be a reflection of adipose tissue lipolysis, ex vivo 
lipolysis was not affected basally or after isoproterenol stimulation in Tnmd 
transgenic mice compared with littermate controls (Figure 2.17, g). These data 
suggest that adipose tissue Tnmd overexpression may have a paracrine effect to 
regulate serum lipid concentrations. 
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Figure 2.17:  Peripheral lipid deposition was reduced in Tnmd transgenic 
mice. (a,b) Livers were isolated from animals fed chow or HFD for 16 weeks. (a) 
H&E staining of liver tissue. Scale bars represent 100 µm. (b) Triglyceride 
content was measured (n=6-8) (c) Gene expression in livers of HFD-fed animals 
(n=9-11) (d) Total cholesterol (n=9-12)  (e) Total triglyceride (n=7-12) and (f) 
Free fatty acid levels (n=7-11, mean±SEM; *p<0.05, **p<0.01, ***p<0.001, by 
Student’s t-test) were assessed in plasma samples from control (Ctrl) and 
transgenic (Tg) animals after 16 weeks of chow (dashed columns) or HFD (solid 
columns). (g) Ex vivo lipolysis in adipose tissue explants from 6-8 week-s old 
mice were fed with a chow diet for 12 weeks. Adipose tissue explants were 
isolated, and lipolysis was stimulated with 10µM isopreterenol for 2 hours 
(mean±SEM; n=6-7, Student’s t-test). 
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Improved insulin signaling in Tnmd-overexpressing mice 
 Because Tnmd transgenic mice displayed decreased adipose tissue 
inflammation and less liver triglyceride content, we hypothesized that these 
animals might demonstrate improved insulin sensitivity. Although Tnmd 
transgenic mice displayed unaltered glucose tolerance in an i.p. glucose 
tolerance test on chow or HFD (Figure 2.18, a), they were remarkably more 
insulin responsive than their control littermates on both chow and HFD during an 
insulin tolerance test (Figure 2.18, b). These data suggest that adipose-specific 
overexpression of TNMD improves systemic insulin sensitivity.  
 In order to determine whether insulin sensitivity signaling was also 
enhanced in insulin-responsive tissues in Tnmd transgenic mice at the molecular 
level in insulin-responsive tissues, HFD-fed control and Tnmd transgenic mice 
were injected with either insulin or PBS. Then 15 minutes later, muscle, liver and 
eWAT were isolated from animals, and analyzed for phospho-Akt levels were 
analyzed as an indicator of insulin signaling. Akt phosphorylation at both S473 
and T308 sites as detected by specific anti-phosphoserine and anti-
phosphothreonine antibodies was significantly increased in Tnmd transgenic 
mouse eWAT compared with littermate controls. Moreover, a trend towards an 
increased Akt phosphorylation at these sites was also observed in both liver and 
muscle, suggesting that in addition to improving adipose tissue insulin sensitivity, 
adipose TMND might also improve insulin responsiveness in other peripheral 
tissues (Figure 2.18, c, d).  
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Figure 2.18: TNMD increased Akt phosphorylation in eWAT and improved 
systemic insulin sensitivity. 
(a) Glucose tolerance and (b) insulin tolerance tests were performed in male 
control (Ctrl) or transgenic (Tg) mice after 12 weeks of chow or HFD 
(mean±SEM; Chow n=12 (control), n=10 (transgenic), HFD, n=11 (control), n=13 
(transgenic), *p<0.05, **p<0.01, ***p<0.001, by Student’s t-test) (c,d) Male 
control (Ctrl) and transgenic (Tg) mice that were fed with HFD for 12 weeks. Mice 
were fasted for 4 hours and tissues were harvested 15 minutes after PBS or 
insulin injection. (c) Western blot analysis and relative protein expression levels 
for p-Akt (S473), p-Akt (T308) and Total Akt in eWAT, liver, and muscle tissue 
lysates. (d) Densitometry analysis of (c) (mean±SEM; n=4 (control and 
transgenic, PBS), n=5 (control, insulin), n=7 (transgenic, insulin), *p<0.05, 
**p<0.01, ***p<0.001, by Student’s t-test).  
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 To further assess what tissues contributed to the enhanced insulin 
sensitivity in Tnmd transgenic mice, hyperinsulinemic-euglycemic clamps were 
performed. The clamp data demonstrated that although glucose levels during the 
clamp were similar, Tnmd transgenic animals had higher insulin sensitivity 
compared with control littermates as assessed by glucose infusion rate (Figure 
2.19, a, b). This difference could be attributed to improved hepatic insulin 
sensitivity because Tnmd transgenic animals displayed decreased hepatic 
glucose production (Figure 2.19, c), whereas no differences were observed in 
tissue-specific glucose uptake (Figure 2.19, d, f). Collectively, these data suggest 
that Tnmd overexpression in murine adipose tissue improves systemic insulin 
sensitivity. 
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Discussion 
 
 Identification of factors that modulate pathological consequences of 
obesity is a vital step towards development of novel therapeutic approaches to 
treatment of insulin resistance and other aspects of metabolic syndrome. In this 
study, we demonstrated that insulin resistant obese individuals have increased 
TNMD expression compared with insulin sensitive controls in the omental 
adipose depot, even when matched for BMI (Figure 2.1). Previous studies 
demonstrated that TNMD is highly expressed in human adipose tissue and its 
expression is further increased in obese conditions (290). Furthermore, genetic 
studies that investigated an association between SNPs and various metabolic 
markers suggested a potential role for this gene in adipose tissue in disease 
(296). Though no difference in TNMD expression was observed in insulin 
resistant versus insulin sensitive patients in subcutaneous adipose tissue depots, 
previous studies that analyzed subcutaneous adipose tissue biopsies 
demonstrated a correlation of TNMD expression, fasting serum insulin levels and 
HOMA-IR in obese patients (290, 318). TNMD expression is predominantly in 
adipocytes compared to the SVF (Figure 2.2), suggesting that the expression 
differences observed in insulin sensitive versus insulin resistant individuals 
mainly result from expression changes in primary adipocytes.  
 A key finding in this study is that TNMD is required for differentiation of 
human SGBS and mouse 3T3-L1 preadipocytes (Figure. 2.4, Figure 2.5). 
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Because TNMD expression is readily stimulated after adipogenic induction and 
continues to increase during differentiation in human cells, we supposed 
hypothesized that the absence of TNMD in preadipocytes would impair early 
differentiation. Consistent with this notion, when TNMD expression was silenced, 
expression of transcription factors involved in adipogenesis such as C/EBPA and 
PPARG was were decreased at early time points of differentiation (Figure 2.8), 
and adipogenesis was impaired. While the exact function of TNMD in this 
process is unclear, TNMD is hereby identified as a novel required factor in early 
stages of adipocyte differentiation. TNMD expression is actually decreased two 
days after induction of 3T3-L1 cell adipogenesis. Therefore, unlike the case in 
human cells, its expression is actually higher in mouse preadipocytes when 
compared to mature adipocytes. However, silencing of TNMD prior to induction 
was sufficient to inhibit the adipogenesis of these mouse preadipocytes, 
indicating that TNMD is required for the initiation of adipogenesis in both species.  
Because it appeared TNMD had a potential role in human cells and 
human patients but was expressed at low levels in mouse adipose tissue, we 
sought to address the role of TNMD in adipose tissue by generating a mouse 
model with higher increased adipose tissue specific Tnmd expression. Such 
adipose-specific Tnmd expression in transgenic mice increased adipogenic and 
lipogenic gene as well as protein expression in eWAT upon high fat diet feeding. 
Notably, PPARγ, one of the major regulators of glucose metabolism and 
adipocyte function (197, 206, 330), was significantly upregulated in the eWAT of 
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HFD-fed Tnmd transgenic mice compared with their control littermates (Figure 
2.14). Because activation of PPARγ has many beneficial effects on adipose 
tissue including improving lipid metabolism and decreasing serum FFAs (331-
333), it can be inferred that TNMD strongly influences adipogenesis through by 
regulating PPARγ expression in vivo. Consistent with these findings in vivo, 
silencing TNMD significantly reduced adipocyte differentiation and adipogenic 
gene expression including PPARG in human and mouse preadipocytes in vitro. 
Many recent studies have described that the ECM has a critical function to 
regulate adipose tissue homeostasis in obesity (226, 229, 233, 334, 335), and 
exogenous signals regulated by ECM proteins are involved in determining the 
fate of mesenchymal progenitor cells. For example, ECM stiffness and 
composition regulates Wnt and TGFβ signaling, which has an inhibitory or, in 
some cases, a stimulatory role in adipogenesis (114). Adipose tissue ECM also 
provides a suitable environment for changes in cell shape during adipogenesis 
and cell expansion (336-339). In this study, we noted a reduction inreduced 
collagen staining in Tnmd transgenic adipose tissue, and collagen and matrix 
metalloproteinase gene expression was also significantly reduced in Tnmd 
overexpressing adipose tissue (Figure 2.15). These results suggest that TNMD 
may promote beneficial adipogenesis at least in part by modulating properties of 
the ECM in adipose tissue. 
In addition to enhancing insulin signaling in eWAT, beneficial effects of 
TMND in liver was also observed, which enhanced systemic insulin sensitivity 
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(Figure 2.18, 2.19). Tnmd transgenic mice had reduced hepatic lipid deposition 
and were more responsive to insulin even in lean, chow-fed conditions. 
Furthermore, hepatic glucose production was reduced in TNMD transgenic 
animals (Figure 2.17). However, it is not established whether these peripheral 
effects are due to the improved lipid sequestration and decreased inflammation 
in eWAT. Future studies will investigate the mechanisms by which adipose 
TNMD function might cause beneficial signaling to other tissues.   
Tnmd transgenic mice had smaller BAT with fewer lipid droplets after HFD 
(Figure 2.16). Furthermore, thermogenic genes Ucp1, Prdm16 and Pparg were 
upregulated in transgenic animals compared with their littermate controls (Figure 
2.16, b). PRDM16 and PPARγ are not only involved in BAT differentiation but 
also in BAT maintenance along with UCP1 (98, 340). However, though TNMD 
was overexpressed in BAT in this model, the thermogenic capacity of the animals 
as assessed by RER remained unchanged (Figure 2.16). Future studies will 
utilize thermoneutral or cold challenge conditions to assess whether TNMD has a 
role in regulation of BAT energy expenditure. 
TNMD expression was higher in the human insulin resistant cohort in our 
study, yet paradoxically mice overexpressing Tnmd in adipose tissue displayed 
improved insulin sensitivity (Figure 2.18, 2.19). In humans, omental fat from 
insulin resistant subjects displays more inflammation and larger adipocytes 
compared with BMI-matched insulin sensitive subjects (300). It is possible that 
the increased inflammation in these insulin resistant subjects arises from 
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enhanced adipocyte death in the insulin resistant omental fat. Indeed, a 
correlation between cell death, insulin resistance, and adipocyte size has 
previously been reported (341). Thus, we speculate that TNMD might be 
increased in insulin resistant omental fat to increase adipocyte replenishment in 
these conditions (212, 325). Indeed, increased preadipocyte proliferation was 
observed in TNMD transgenic animals (Figure, 2.13), which could promote 
healthy tissue expansion. It is also possible that either the omental fat 
microenvironment or endocrine signals associated with the insulin resistant state 
can contribute to TNMD overexpression, perhaps as a compensatory mechanism 
to promote adipogenesis and increase insulin responsiveness. Finally, most of 
the insulin resistant human subjects in our cohort had been treated for different 
amounts of time with various medications including thiazolidinediones before 
bariatric surgery and tissue collection. Thus, we cannot rule out the possibility 
that TNMD expression was increased in insulin resistant subjects as a result of 
these medications. 
In summary, our study reveals that the gene TNMD, which is highly 
expressed in human adipose tissue, encodes a protective adipose tissue factor 
that promotes preadipocyte proliferation, adipogenesis, adipose tissue health, 
and insulin responsiveness in vivo. The data presented herein support the 
hypothesis that TNMD contributes to beneficial visceral adipose tissue expansion 
that protects against metabolic dysfunction. Because adipose TNMD expression 
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improves insulin sensitivity systemically, it may have potential as a therapeutic 
target to protect metabolic homeostasis in obesity. 
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CHAPTER III 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
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The consequences of obesity related to adipose tissue dysfunction include 
insulin resistance and impaired glucose homeostasis. Therefore, identifying novel 
mechanisms that regulate adipose tissue function in the context of obesity is 
crucial to further our understanding of the pathogenesis of metabolic diseases. 
The work presented here suggests that TNMD enhances adipose tissue function. 
In a genome wide microarray study, TNMD was elevated in omental adipose 
tissue of insulin resistant patients compared with insulin sensitive subjects of 
similar BMI (Figure 2.1 a, c-e). Furthermore, previous studies demonstrated that 
TNMD expression is very high in human adipose depots and further increases 
upon obesity (290). Therefore, I aimed to address two following three questions:  
1. Is TNMD required for adipocyte differentiation? 
2. Does TNMD promote adipose tissue expansion and enhance adipose 
tissue function in vivo? 
 To address the first question, I utilized both human (SGBS) and mouse 
(3T3-L1) cells. Using siRNA-mediated knockdown, I demonstrated that TNMD is 
required for adipocyte differentiation in both human and mouse cells as assessed 
by multiple biochemical methods. My results indicated that TNMD is also 
necessary for the induction of adipogenic gene expression during adipogenesis 
(Figure 2.4, 2.5). Gene chip analysis and qRT-PCR validation studies revealed 
that TNMD depletion attenuated adipogenic transcription factor and target gene 
induction in the first day of differentiation (Figure 2.7, 2.8).  
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To address the second question, I generated a transgenic mouse model 
that expresses a C-terminal FLAG tag on TNMD specifically in adipose tissue 
using the adiponectin promoter. Specific and significant expression of TNMD was 
determined in both white and brown adipose depots (Figure 2.10). For metabolic 
characterization, I fed transgenic and control mice either chow (normal) or HFD 
and measured weight gain over time. No difference in body weight was observed 
between transgenic and control littermates (Figure 2.11). However, eWAT weight 
was significantly increased in the transgenic animals fed with HFD (Figure 2.12). 
I then assessed whether the increase in eWAT weight was mediated by 
adipocyte hyperplasia or hypertrophy by measuring cell size. No cell size 
difference was observed in WAT depots isolated from transgenic and control 
animals (Figure 2.12). These data suggested that eWAT expansion driven by 
TNMD overexpression occurs via hyperplasia but not hypertrophy. Lipogenic 
gene expression was consistently increased in the eWAT of transgenic animals 
suggesting an increased capacity for fat sequestration (Figure 2.13). 
Furthermore, histology analysis indicated a decrease in immune cell content 
within eWAT of transgenic mice compared with control animals (Figure 2. 12). 
Consistent with these results, using trichrome staining, reduced collagen 
accumulation was also observed in the eWAT of transgenic mice (Figure 2.15). 
By measuring triglyceride levels and analyzing histology samples, I also 
assessed lipid deposition in peripheral tissues such as liver observed reduced 
hepatic steatosis in TNMD transgenic animals compared with controls (Figure 
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2.17). These results suggested that increased capacity of eWAT for lipid storage 
prevented free fatty acid deposition in non-adipose tissues. Systemic insulin 
resistance was also improved in the TNMD overexpressing mice (Figure 2. 18, 
2.19).  
In conclusion, the data in this thesis suggests a role for TNMD in 
adipocyte differentiation and healthy adipose tissue expansion during obesity. 
Furthermore, these results provide a novel model where eWAT is expanded, yet 
systemic insulin responsiveness is improved, which supports the notion that 
adipose tissue health matters more than adipose tissue mass in the context of 
obesity.  
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Figure 3.1 
 
 
Figure 3.1: A model of TNMD action in adipose tissue 
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TNMD as a novel regulator of adipogenesis and beneficial adipose tissue 
expansion 
 To identify novel molecules that are involved in promoting insulin 
resistance or conversely maintaining insulin sensitivity in obese subjects, our 
laboratory performed a microarray analysis using whole adipose tissue samples 
isolated from subcutaneous and visceral adipose depots of morbidly obese 
patients who underwent bariatric surgery. Using the same approach, our 
laboratory previously showed that the inflammatory gene signature, especially 
inflammatory chemokines such as CCL2, CCL3 and CCL4 were significantly 
increased in omental but not subcutaneous fat of insulin resistant patients 
compared with insulin sensitive subjects. These data demonstrated that 
independent of BMI, macrophage infiltration and chemokine secretion is 
associated with insulin resistance in humans (300). In the same study, many 
genes were differentially expressed between insulin resistant and insulin 
sensitive patients. Here, I focused on TNMD because 1) it was significantly 
upregulated in insulin resistant omental adipose tissue, which was verified by 
qRT-PCR and Western Blot analysis (Figure 2.1), and 2) TNMD expression was 
limited almost exclusively to primary adipocytes in human adipose tissue (Figure 
2.2). Adipose tissue immune cell content rapidly increases during obesity and is 
involved in the pathogenesis of insulin resistance (223, 244). Therefore, it was 
important to rule out that the increase in TMND expression that was observed in 
whole adipose tissue samples was not due to an increase in the immune cell 
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population. The predominant expression of TNMD in primary adipocytes 
suggested that TNMD is concentrated in this cell type. Further experiments are 
needed to compare TNMD expression in isolated primary adipocytes from insulin 
resistant and insulin sensitive subjects.  
Surprisingly, no difference in TNMD expression between insulin resistant 
and insulin sensitive subjects was observed in subcutaneous adipose tissue, 
which could be attributed to differences in gene expression among white adipose 
depots (89).  Interestingly, TNMD is responsive to glucocorticoid treatment in 
vitro (342). Even though systemic cortisol levels do not change in obese 
subjects, increased cortisone levels have been demonstrated in obese visceral 
adipose tissue. 1-beta hydroxysteroid dehydrogenase 1 (HSD1), a reductase 
enzyme that generates cortisol in vivo, has higher activity in stromal cells isolated 
from omental adipose tissue compared with those isolated from subcutaneous 
depots (94). Cortisol levels or HSD1 activity in omental fat of human subjects 
from both groups has not been measured. It would be interesting to assess 
whether TNMD expression is upregulated by changes in local glucocorticoid 
levels in omental adipose depots of insulin sensitive vs. insulin resistant patients.  
Because the SVF includes adipocyte precursors, the very low expression 
of TMND in this fraction and comparatively high expression in primary adipocytes 
suggested that TNMD is responsive to adipogenic differentiation. To address this 
question, I utilized SGBS preadipocytes as a relevant human cell culture model. 
Indeed, TNMD was stimulated several hundred fold upon differentiation. 
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Adipogenic differentiation was confirmed by assessing the expression of 
adipogenesis markers such as ADIPOQ and PPARG (Figure 2.3, a). Validation 
of these results using other human adipocyte cell culture models such as human 
adipose derived stromal cells (hADSCs) could be performed in the future.  
TNMD is induced very early in the adipocyte differentiation program and 
has a similar expression pattern to C/EBPα (Figure 2.3, b). TNMD expression 
started to increase 18 hours after induction and continued to increase throughout 
adipogenesis in human cells. These results suggest 1) TNMD is an adipogenic 
gene that is involved in adipocyte differentiation and has a function in mature 
adipocytes, 2) TNMD expression is regulated by adipogenic transcription factors 
C/EBPα and PPARγ or 3) TNMD acts upstream of adipogenic transcription 
factors. To test the first hypothesis, TNMD was silenced in preadipocytes two 
days prior to adipogenic induction, and silencing TNMD significantly attenuated 
adipogenesis in SGBS cells (Figure 2.4). Because TNMD is upregulated by 
differentiation, diminished adipogenesis itself could also contribute to low TNMD 
expression compared with control cells transfected with scrambled RNA (Figure 
2.4, e). Thus, these results suggest that TNMD induction is required for 
adipogenesis and adipogenic gene expression. Mouse adipocyte cell line 3T3-
L1s are by far the most common cell line used to study adipogenesis and 
adipocyte biology (138). TNMD, however, demonstrated a different expression 
profile in these cells. As opposed to human SGBS preadipocytes, TNMD 
expression decreased after the second day of differentiation in 3T3-L1s (data not 
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shown). However, TNMD knockdown diminished differentiation in 3T3-L1 cells as 
well. This difference between human and mouse adipocytes in terms of TNMD 
expression during differentiation is interesting and suggests that even at low 
levels of expression, its effects are significant. Further studies will address how 
TNMD is regulated in different species. Such different expression patterns 
between mouse and human raised an issue about potential off-target effects of 
siRNA-mediated knockdown. Rescue experiments using expression vectors with 
mutated siRNA target sites would further support our findings. Alternatively, 
different oligos targeting TNMD gene could be used to rule out the possibility of 
off-target phenotype. However, overexpressing genes by transfection is 
technically challenging in SGBS and 3T3-L1 cells yet overexpression via lentiviral 
or adenoviral infection could create artificial results due to unnecessarily high 
expression of the target gene or off target effects of the virus.  
Even though in vitro results strongly suggest that TNMD is required for 
adipogenic differentiation, mechanistic details on how TNMD regulates 
adipogenesis and adipogenic gene expression are still unclear. Hence, the 
molecular pathways that are altered upon TNMD knockdown were investigated in 
unstimulated and stimulated cells using microarray analysis. These experiments 
further supported the finding that silencing TNMD attenuated stimulation of 
adipogenic genes (Figure 2.7, a). The microarray data for some transcription 
factors such as C/EBPα were verified at both mRNA and protein levels. These 
findings suggest that TNMD might be an upstream regulator of this transcription 
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factor. However, experiments to address whether the reduction in C/EBPα 
expression is the result or the cause of diminished adipogenesis could be 
performed in the future.  
Next, I asked whether the phenotype observed upon TNMD depletion is 
cell autonomous or non-cell autonomous because TNMD has been predicted to 
be a plasma membrane protein with a large extracellular portion (275, 285). 
Considering that cell-cell contact is required for adipogenic differentiation (114), I 
hypothesized that TNMD might be involved in the interaction of adjacent cells. 
TNMD also has a putative cleavage site, and studies suggested that the cleaved 
C-terminal portion is active (285). Interestingly, I also demonstrated that when 
overexpressed in SGBS preadipocytes, TNMD is cleaved and the C-terminal 
peptide is released into culture media (Figure AI-1). Conceivably this peptide 
might act on neighboring cells such as adipocytes precursors, or could reach 
other tissues through circulation. To address these questions, I co-cultured non-
transfected cells and siTNMD transfected cells together to observe the 
consequence on adipogenesis. In this experiment, co-culturing non-transfected 
and TNMD silenced cells resulted in an approximate 50% reduction in Oil Red O 
staining, which suggested a cell autonomous role for TNMD in adipogenesis. 
Even though these data do not rule out the possibility that TNMD is cleaved and 
secreted, it provides evidence that the secreted product, at least at endogenous 
levels, is not sufficient to rescue reduced adipogenesis in the absence of TNMD. 
Further studies using conditioned media from TNMD overexpressing cells could 
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also be performed to assess whether TNMD acts in a cell autonomous manner to 
promote adipogenesis.  
Because TNMD expression increased remarkably during differentiation, I 
hypothesized that TNMD may have additional effects on adipocyte biology. 
Future studies using human in vitro adipocyte models are needed to address 
whether TNMD functions in the metabolic processes such as lipogenesis, 
lipolysis or glucose uptake and if so, what is the mechanism whereby TNMD 
regulates these processes.  
Adipose tissue is a complex organ in which adipocytes interact with other 
cells types in addition to the extracellular matrix (24, 223). I aimed to address my 
metabolic questions in the context of whole adipose tissue. Therefore, an in vivo 
model was developed. Expression of Tnmd in mouse adipose depots is low or 
below detection (290). Therefore, an adipocyte-specific adiponectin promoter-
driven Tnmd overexpression model was generated. qRT-PCR and Western Blot 
analysis of TNMD confirmed very low or undetectable levels of TNMD in mouse 
adipose depots (Figure 2.10, data not shown). Moreover, Tnmd transgenic mice 
displayed a significant and specific expression of Tnmd in eWAT, iWAT and BAT 
(Figure 2.10). Surprisingly, Tnmd overexpression in adipose tissue did not affect 
total body weight gain (Figure 2.11, a). However, individual adipose depots from 
animals that were fed HFD revealed that TNMD overexpression caused a 
significant increase eWAT but not subcutaneous depot expansion (Figure 2. 11, 
b). These results raised two questions: 1) Did eWAT in transgenic animals 
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expand via hypertrophy or hyperplasia? and 2) Does TNMD control adipose 
tissue expansion? To pinpoint the mechanism of adipose tissue expansion, cell 
size was measured in histology sections, and the average cell size from both 
adipose depots (eWAT and iWAT) was unchanged (Figure 2.12, a). These 
results suggested that adipocyte number was increased in HFD-fed transgenic 
animals. Thus, earlier time points were investigated during HFD feeding to 
observe the formation of new and smaller adipocytes. Adipose depot weight and 
adipocyte size was assessed in animals fed HFD for only 4 weeks, and no 
difference in either adipose depot weights or adipocyte size was observed. 
These data suggest that hyperplasia occurs at the late time points of the HFD 
challenge. This conclusion is consistent with two models that have been recently 
published. In the first model, Scherer and colleagues demonstrated that eWAT 
expands by both hypertrophy and hyperplasia in mice, the latter of which occurs 
after 8 weeks of HFD feeding (133). In the second model, preadipocyte 
proliferation was increased in the first week of HFD, but newly differentiated 
adipocytes could not be detected for 8 weeks (220). It is unclear when 
preadipocytes complete differentiation and start expanding in size during diet 
induced obesity; addressing this question will be highly informative.  
Reduced tenocyte proliferation has been reported in Tnmd null mice (277). 
Therefore, I hypothesized that TNMD might also promote preadipocyte 
proliferation, and in vivo BrdU incorporation into preadipocytes isolated from 
Tnmd overexpressing mice was indeed increased (Figure 2.13). These results 
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suggested that enhanced preadipocyte proliferation in TNMD transgenic animals 
resulted in hyperplastic eWAT. One could argue that the adiponectin promoter 
would drive Tnmd expression in mature adipocytes rather than precursors; thus, 
effects in preadipocyte proliferation cannot be explained by Tnmd 
overexpression. Although cell culture experiments suggested that the effects of 
TNMD were cell autonomous, it remains to be tested whether TNMD increased in 
vivo preadipocyte proliferation in a cell autonomous manner. Another important 
question is whether TNMD promotes in vivo differentiation of preadipocytes that 
reside in the eWAT. Future studies using in vivo tracer models can address this 
question. Alternatively, tracing BrdU labeled adipocytes would be informative to 
determine whether labeled preadipocytes actually make new adipocytes in the 
later time points of HFD challenge.  
Adipose tissue de novo lipid synthesis is reduced in obesity (45). To 
investigate whether adipogenic and lipogenic gene expression were increased in 
eWAT of Tnmd transgenic animals, I performed qRT-PCR and Western Blot 
analysis, and the expression of lipogenic genes such as Srebp1c, Fasn and Acly 
was significantly increased in transgenic animals compared to control littermates 
(Figure 2. 14, a). Consistent with our in vitro adipogenesis experiments, PPARγ 
was also elevated in the eWAT of transgenic animals (Figure 2.14, b,c). These 
data suggest that TNMD enhances lipid synthesis in eWAT, thereby promoting 
efficient lipid sequestration in this depot during obesity. However, it should be 
taken into consideration that adipocyte-specific gene expression in whole 
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adipose tissue samples could appear to decrease when the number of other cell 
types elevates. Therefore, increased immune cell infiltration in the control eWAT 
might contribute to the apparent decrease in adipocyte-specific gene expression 
in whole adipose tissue. This possibility could be ruled out by assessing gene 
expression profiles in isolated SVF and primary adipocytes. Even though no 
difference in tissue weight or cell size was observed, it would be informative to 
determine whether de novo lipogenesis is improved in subcutaneous adipose 
depots. Ex vivo lipogenesis assays using eWAT and iWAT isolated from chow 
fed animals did not reveal any difference in lipogenesis between the transgenic 
and control mice. However, there were some potential pitfalls with this 
experiment. First, ex vivo conditions do not always fully represent the in vivo 
tissue environment and could create artificial results. Second, chow animals were 
used for this experiment, and differences might only be observed in animals 
challenged with HFD.  
TNMD may have anti-angiogenic effects (283, 285). One could expect that 
overexpression of a putative anti-angiogenic protein can blunt vessel 
dissemination during adipose tissue expansion. Therefore, the role of TNMD in 
adipose tissue angiogenesis was elucidated by isolectin staining of the 
vasculature and vessel density quantification. Consistent with previous results 
reported in Tnmd knockout mice, there was no effect of adipose-specific Tnmd 
overexpression on the adipose tissue vasculature (Figure 2.15) (277). These 
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results suggest that TNMD promotes eWAT expansion independent from 
modulating the tissue vasculature.   
TNMD has been extensively studied in the context of tendon tissue. 
Studies show that TNMD knockout affects collagen matrix formation and 
structure (277). Because the ECM can affect adipocyte differentiation, 
metabolism and expansion (223, 336, 337), I investigated the expression of ECM 
components by qRT-PCR and structure by Masson’s Trichrome staining in 
adipose tissue and demonstrated that collagen accumulation was reduced in 
Tnmd overexpressing mice. Trichrome staining does not distinguish types of 
collagen; therefore, it would be useful to determine which types of collagen are 
differentially expressed in the control and TNMD transgenic adipose tissue, as 
collagen VI has adverse metabolic effects in adipose tissue (233, 335). Gene 
expression analysis partly confirmed reduced collagen expression in the eWAT 
of transgenic animals. Interestingly, the expressions of some matrix 
metalloproteinases (MMPs) were also downregulated in the transgenic animals 
(Figure 2.15, d). This result was rather contradictory to the reduction in collagen 
expression because tissue MMP depletion is often characterized by collagen 
accumulation (159). The decrease in MMP12 (macrophage metalloelastase) 
could be attributed to a reduction in macrophage content in Tnmd overexpressing 
eWAT (Figure 2.12, a Figure 2.15, e). However, MMP activity inhibitors (TIMP) 
expression levels need to be analyzed. Interestingly, TGFβ, SMAD2 and SMAD3 
mRNA levels were also reduced in the transgenic animals. Although the in vivo 
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and in vitro effects of TGFβ on adipogenesis and adipose tissue formation is 
somewhat contradictory (114), it could be interesting to explore whether TNMD 
promotes hyperplasia in adipose tissue via modulating TGFβ signaling. 
As mentioned above, Tnmd overexpression also resulted in reduced 
immune cell infiltration and crown like structure formation in adipose tissue. 
mRNA levels of proinflammatory molecules such as Ccl2 were also diminished 
(Figure 2.12). There is a vicious cycle in obese adipose tissue whereby cellular 
stress in adipocytes causes pro-inflammatory cytokine secretion, which can 
attract macrophages, in turn furthering adipose tissue inflammation (262). Thus, 
it would be interesting to address whether TNMD lessens cellular stress by 
improving the tissue environment in favor of healthier expansion, or alternatively 
whether TNMD regulates inflammatory pathways and decreases inflammation in 
obese adipose tissue.  
Tnmd was also overexpressed in BAT of transgenic mice (Figure 2. 10). 
Reduced lipid deposition was observed as assessed by histology, consistent with 
reduced BAT weight in the transgenic animals. Furthermore, Ucp1 expression 
increased in the Tnmd overexpressing mice. However, metabolic cage studies 
detected no difference in respiratory exchange rate or oxygen consumption. 
Though BAT seemed to have higher activity in transgenic animals, it did not 
contribute to systemic energy expenditure at room temperature. Performing the 
metabolic experiments in thermoneutral conditions in which cold stress is 
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eliminated for mice could give a better insight into whether BAT is involved in the 
systemic metabolic actions of TNMD.  
It was also important to explore whether apparent healthy expansion of 
visceral adipose tissue resulted in an inhibition of peripheral lipid deposition. 
Histological examination and reduced triglyceride content clearly demonstrated 
that hepatic steatosis was prevented in the transgenic animals, which was 
consistent with reduced whole liver weight. These data suggest that better 
sequestration of the lipids in eWAT protected the liver from TG accumulation, 
even in very obese conditions. Genes controlling de novo lipogenesis and lipid 
storage were measured in this tissue. Hepatic glucose production in the 
transgenic animals was also attenuated in the basal state (Figure 2.19, c). 
Therefore, it would be interesting to investigate whether gluconeogenesis was 
altered in the transgenic animals.  
 Next, I addressed systemic metabolic health in Tnmd transgenic mice. 
Even though no difference was observed between genotypes in a GTT, Tnmd 
overexpressing mice were more insulin sensitive as assessed by ITT (Figure 
2.18).  Furthermore, increased insulin-stimulated AKT phosphorylation was 
observed in eWAT (Figure 2.18, c, d). Healthier adipose tissue expansion is 
associated with improved systemic insulin responsiveness, and the ITT 
consistently demonstrated a profound metabolic difference between control and 
transgenic animals. Insulin-dependent, tissue-specific glucose uptake in was 
assessed during a hyperinsulinemic-euglycemic clamp study. In this study, a 
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trend to increased glucose uptake in BAT and skeletal muscle was observed in 
TNMD transgenic mice compared with controls. Interestingly, the liver was more 
insulin sensitive in Tnmd transgenic mice than controls, and lower hepatic 
glucose production was also observed in basal conditions. Furthermore, there 
was a significant increase in the glucose infusion rate during the clamp in 
transgenic mice compared to control littermates (Figure 2.19). Therefore, 
improved insulin signaling in the eWAT of Tnmd transgenic animals is a reflection 
of healthier adipose tissue, and the clamp study demonstrates that the liver is 
also a contributing factor. Inter communication between eWAT and liver should 
also be considered.  
In conclusion, the data in this thesis provide evidence for a beneficial role 
of TNMD in adipocyte differentiation and adipose tissue function. This work also 
advances understanding of adipose tissue expansion during obesity. Visceral 
adipose tissue has long been associated with metabolic diseases (88, 266, 304). 
Here, selective visceral adipose depot expansion was actually beneficial because 
adipocyte number and fat sequestration was maximized while cellular stress was 
abated. Thus, TNMD could be an important therapeutic target to promote the 
healthy visceral adipose tissue expansion during obesity, and more importantly, 
to reverse adipocyte dysfunction in the disease state.  
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Future Directions 
TNMD has been widely used as a differentiation marker for tenocytes 
(273, 277, 286). However, TNMD’s function has not been fully understood. 
Defining the intracellular localization of TNMD might give insight into this 
protein’s function. Based on sequence TNMD is predicted to be a type II 
transmembrane protein (275, 343). However, contradictory results on the 
intracellular localization of TNMD have been reported. It has been detected in 
various locations in the cell such as plasma membrane, golgi and nuclear 
envelope. Even though endogenous protein has been detected in some of these 
studies, proper controls including TNMD null cells have not been used (286, 
288). Moreover, many of these studies utilized an overexpression approach, 
which can give rise to artificial results. Therefore, careful analysis of intracellular 
localization of TNMD in adipocytes with a specific antibody that can detect the 
endogenous protein will be useful in terms of understanding its possible 
functions. Moreover, fractionation studies using human adipose tissue where 
TNMD is expressed at high levels will be helpful to assess localization.  
Future work identifying the molecular mechanisms by which TNMD 
achieves its metabolic effects systemically and locally will be of great importance. 
Unbiased techniques such as RNAseq or proteomics in combination with genetic 
studies including mutation analyses targeting SNPs in the human TNMD gene 
that are associated with metabolic parameters (potentially using CRISPR 
technology) will be very informative.  
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  Even though in vitro adipogenesis has been very well studied using cell 
culture systems, in vivo mechanisms that are implicated in adipogenesis are 
incompletely understood (114). We were able to demonstrate that TNMD 
contributes to hyperplastic adipose tissue expansion through promoting 
preadipocyte proliferation in the first week of HFD. However, the question 
whether TNMD also stimulated adipogenesis in the visceral adipose depot is yet 
to be addressed. Crossing Tnmd transgenic mice with tamoxifen inducible 
Adiponectin-CreER mT/mG (220) reporter line or doxycycline inducible Cre-LacZ 
reporter line (133) could be the proper approach to address this question. 
Furthermore, administering the potentially secreted portion of TNMD to these 
reporter lines will be helpful to determine the effect of TNMD on adipogenesis in 
vivo. In both cases, observing new adipocyte formation at greater levels in 
transgenic or TNMD administered animals would further prove that TNMD 
promotes hyperplastic adipose tissue expansion in vivo.  
 The most significant future work on TNMD in terms of impact on the field 
might be to determine whether it is a novel adipokine, a secreted factor that acts 
locally or systemically to affect adipose or other tissue function. Important 
remaining questions related to this include assessing whether TNMD is in fact 
secreted, and whether the putative secreted peptide functions locally or 
circulates systemically. If the peptide circulates, does it function as an endocrine 
factor that regulates peripheral tissue function? These questions could be 
answered using parabiosis experiments in which the circulation of a wild type 
124
mouse is attached to a Tnmd transgenic mouse. If TNMD acts as a secreted 
factor or alternatively stimulates the secretion of other factors from eWAT, 
metabolic improvements should also be observed in the wild type animals in 
obese conditions. If no effect is observed in parabiosis experiments, the data 
would suggest that TNMD might act in a paracrine fashion. Even though TNMD 
is likely to be cleaved from its putative furin site, identifying the exact sequence of 
this secreted portion will be important in terms of producing the recombinant 
peptide and assessing its physiological effects. Alternatively, generating a 
transgenic mice with non-cleavable furin site or taking a loss-of-function 
approach by using neutralizing antibodies will give better insight into the possible 
role of TNMD as a beneficial adipokine.   
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APPENDIX I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126
Introduction, Results and Discussion 
 
 Adipose tissue is one of the biggest endocrine organs in the body (62). 
Many studies have demonstrated that peptide hormones secreted from 
adipocytes have various biological effects (262).  Adipose driven cytokines-also 
known as adipokines- regulate not only adipose tissue function but also 
metabolic homeostasis in the peripheral tissues such as muscle and liver (344). 
Moreover, ECM proteins that are processed and released from adipocytes into 
the adipose tissue microenvironment can play roles in the adipocyte expansion 
and preadipocyte proliferation (345). Full characterization of adipocyte secretome 
and ECM composition is unlikely complete. Therefore, identifying novel 
adipokines or ECM-related proteins that are implicated in the adipose tissue’s 
metabolic function is of great importance.  
 Recent studies suggested a metabolic role for TNMD (290, 296, 318). We 
also identified it as a novel regulator of adipogenesis and visceral adipose tissue 
expansion in diet induced obesity. TNMD promoted preadipocyte proliferation 
and hyperplastic adipose tissue expansion upon high fat diet feeding and mice 
overexpressing TNMD selectively in the adipose tissue demonstrated improved 
systemic insulin sensitivity in obese conditions (Chapter II). Studies also 
suggested a role for TNMD in the tendon tissue as TNMD null mice 
demonstrated disorganized collagen fibrils in the tendon tissue (277). We also 
demonstrated a reduced collagen accumulation in Tnmd overexpressing adipose 
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tissue (Chapter II). In the light of these findings, we sought to address two 
important questions:  
1) Is TNMD processed and secreted into local environment or blood 
circulation?   
2) Does TNMD interact with ECM components?  
 In order to address the first question, we overexpressed TNMD with N-
terminal 3HA and C-terminal Flag tag using an adenoviral construct. We used 
3HA expressing empty virus infected and non-infected cells as controls. Cells 
were incubated in a serum free media supplemented with 33 uM biotin, 17 uM 
pantothenic acid for 48 hours after the infection (Figure A.1, a). Overexpression 
of full length TNMD was confirmed in lysates using an antibody against a peptide 
in the extracellular domain of TNMD (Figure A.1, b). We also analyzed the 
concentrated media by Western Blot. Surprisingly, we detected a band around 15 
kDa in the media isolated from TNMD overexpressing cells but not from control 
cells. These results suggest that TNMD might be cleaved by endopeptidases and 
secreted into extracellular environment (Figure A.1, c). Interestingly, we also 
observed a similar size band in the lysates and this band was slightly smaller 
than the one in the media, which suggest that TNMD might be processed inside 
the cell and secreted through canonical secretion pathway. Moreover, we were 
able to detect the cleaved product with Flag antibody, whereas no band was 
detected using HA antibody. These results provided evidence that C-terminal 
domain of TNMD is secreted into media.  
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 We have demonstrated that TNMD overexpression in the adipose tissue 
altered the collagen accumulation and the expression of ECM proteins at the 
mRNA level.  A role for tenomodulin in modulating ECM interactions was also 
suggested by proteomics data obtained in SGBS cells. We overexpressed TNMD 
using an adenoviral vector expressing TNMD with HA (N-terminus) and Flag (C-
terminus) tags and immunoprecipitated TNMD-associated proteins to identify 
potential binding partners. In proteomics analysis, we found several proteins that 
are either located in adipose tissue ECM or involved in processing ECM proteins 
(Table A.1). Even though validation studies are needed, these results suggest 
that TNMD may contribute to healthy visceral adipose tissue expansion through 
direct interaction with extracellular matrix proteins or function as an extracellular 
matrix protein that generates a local environment to favor adipocyte expansion 
and preadipocyte proliferation.  
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Table A.1 
Protein Name Gene Symbol 
Spectral Counts 
Ad-HA-Control Ad-3HA-TNMD–Flag 
TGFβ-induced protein ig-h3 TGFBI 2 29 
Thrombospondin 1 THBS1 3 17 
Periostin POSTN 0 12 
Metalloproteinase inhibitor 3 TIMP3 2 10 
Ugl-Y3 (Fibronectin Precursor) FN1 3 10 
Plasminogen activator inhibitor 1 SERPINE1 0 8 
Protein-lysine 6-oxidase LOX 0 8 
Glypican 1 GPC1 0 6 
Galectin 7 LGALS7 2 6 
Connective tissue growth factor CTGF 0 5 
Tenascin C TNC 0 4 
Emilin 1 EMILIN1 0 4 
Collagen alpha-2 (VI) chain COL6A2 0 3 
Matrix metalloproteinase 14 MMP14 0 2 
Galectin-3-binding protein LGALS3BP 0 2 
Metalloproteinase inhibitor 1 TIMP1 0 2 
 
Table A.1: ECM proteins or ECM-protein processing enzymes interacting 
with TNMD 
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 Whether TNMD is circulated in the body is yet to be addressed. We are 
currently analyzing serum samples obtained from Tnmd overexpressing mice. 
Detecting TNMD in the serum and addressing the question whether TNMD that 
potentially secreted from visceral adipose tissue acts on liver will provide an 
insight into our understanding of how TNMD regulates systemic lipid and glucose 
metabolism. Moreover, characterizing the secreted portion of TNMD will be very 
informative for design and production of a recombinant peptide to test the 
physiological function of secreted TNMD. Given that overexpressing TNMD in 
adipocytes improved systemic insulin resistance in obese mice and that secreted 
portion potentially posses a physiological function, TNMD could be considered as 
a novel therapeutic target.  
 
Experimental Procedures 
 
Cell Culture  
 Simpson Golabi Behmel Syndrome (SGBS) cells were cultured in 
DMEM/F12 media supplemented with 10% fetal bovine serum, 33 uM biotin, 17 
uM pantothenic acid, 100 units ml-1 penicillin and 0.1 mg ml-1 streptomycin. Cells 
were seeded in 15 cm dishes and infected with Ad-3HA-TNMD-Flag or Ad-3HA-
Control virus. Infection media was changed after overnight incubation. Cells were 
washed and incubated in serum free media supplemented with 33 uM biotin, 17 
uM pantothenic acid, 100 units ml-1 penicillin and 0.1 mg ml-1 streptomycin for 48 
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hours. Media was collected and centrifuged for 5 min at 1500 rpm. Supernatant 
was concentrated in protein concentrators with 2000 Da molecular weight cut off 
(Vivaspin 2, Sartorius).  
 
Western Blotting 
 Cell lysates were prepared using RIPA buffer (150 mM NaCl, 50 mM Tris 
pH 7.4, 1% sodium deoxycholate, 1% NP-40, 0.2 % SDS, 50 mM EDTA) 
containing 1X HALT protease and phosphatase inhibitors (Thermo Scientific). 
Total protein was separated on 15% SDS-PAGE gels and transferred to 
nitrocellulose membranes. Membranes were blocked with 5% milk solution in 
TBS-T and immunoblotted with an antibody generated against 
NGIEFDPMLDERGYC peptide from C-terminus of TNMD (Rockland, 1:5000), 
HA (Cell Signaling, 1:1000), FLAG (Cell Signaling, 1:1000) and actin (Sigma, 
1:5000) antibodies.  
 
Immunoprecipitation and Proteomics Analysis 
 SGBS cells were infected with Ad-3HA-TNMD-Flag or Ad-3HA-Control 
virus. After 48 hours, cells were lysed with lysis buffer (1% NP40, 50 mM Tris pH 
7.4, 150 mM NaCl, 5 mM EDTA, 1X HALT protease and phosphatase inhibitors). 
1 mg total lysate from each sample was incubated overnight with HA antibody 
(Cell Signaling, 3724) at 40C, which was followed by incubation with Protein A for 
an additional hour. Samples were loaded on SDS-PAGE (Biorad Mini-Protean 
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TGX 4-20%). Proteomics analysis was performed by UMass Medical School 
Proteomics and Mass Spectrometry Core Facility.  
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